Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
10 "Jun Ma"
Filter
Filter
Article category
Keywords
More +
Publication year
Authors
More +
Funded articles
More +
Original Articles
Breast cancer
Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer
Lingjun Ma, Ran Zheng, Lingyun Xu, Ying Zhu, Hong Yin, Xiaoqing Zhang, Rong Deng, Jue Wang, Xiaoming Zha
Cancer Res Treat. 2026;58(2):501-512.   Published online April 21, 2025
DOI: https://doi.org/10.4143/crt.2024.1200
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Dual anti–human epidermal growth factor receptor 2 (HER2) drugs have become the standard regimen for neoadjuvant systemic treatment (NST) to HER2-positive breast cancer patients. However, the efficacy varies greatly among patients with different HER2 protein expression levels.
Materials and Methods
A total of 575 HER2-positive breast cancer patients from multiple centers throughout China from 2013 to 2022 were retrospectively analyzed. We compared clinicopathological features in different HER2 immunohistochemistry classes (HER2 2+/in situ hybridization [ISH] + or HER2 3+), and their difference in response to NST and survival with single or dual anti-HER2 drugs. Drug sensitivity assays were used to evaluate different efficacy of anti-HER2 drugs in vitro.
Results
Compared to HER2 3+ subgroup, the HER2 2+/ISH+ group had a higher proportion of hormone receptor–positive status (48.7% vs. 76.1%, p < 0.001), more HER2 protein loss after NST, lower pathological complete response (pCR) rate (46.07% vs. 16.24%, p < 0.001), and tended to have worse disease-free survival (DFS). In HER2 2+/ISH+ patients, treated with pertuzumab and trastuzumab in combination had no significant improvement in pCR (19.12% vs. 12.24%, p=0.287) and DFS (p=0.908) than using alone. Drug sensitivity assay showed poor efficacy with dual anti-HER2 drugs in HER2 2+/ISH+ cell lines; however, fam-trastuzumab deruxtecan drugs had a satisfactory effect.
Conclusion
Owing to the differences in clinicopathological features and treatment efficacy, we considered the HER2 2+/ISH+ group to be a distinct subtype and defined it as the HER2-moderate–positive subgroup. In this subgroup, dual anti-HER2 drugs did not exert significant improvement in pCR and DFS. Therefore, treatment optimization is warranted, with antibody-drug conjugate drugs as potential options.
  • 3,641 View
  • 157 Download
Close layer
Head and Neck Cancer
Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area
Ji-Jin Yao, Li Lin, Tian-Sheng Gao, Wang-Jian Zhang, Wayne R. Lawrence, Jun Ma, Ying Sun
Cancer Res Treat. 2021;53(3):657-670.   Published online December 7, 2020
DOI: https://doi.org/10.4143/crt.2020.899
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to develop web-based nomograms to precisely predict survival outcomes in patients with non-metastatic nasopharyngeal carcinoma (NPC) in an endemic area.
Materials and Methods
A total of 10,126 patients who underwent radical intensity-modulated radiotherapy at Sun Yat-sen University Cancer Center (SYSUCC) from 2009 to 2015 were analyzed. We assigned patients into a training cohort (SYSUCC-A, n=6,751) and an internal validation cohort (SYSUCC-B, n=3,375) based on computer-generated random numbers. Patients collected from Wuzhou Red Cross Hospital (WZRCH) between 2012 and 2015 were used as the independent external validation cohort (WZRCH, n=450). Concordance index (C-index) was used to determine predictive accuracy and discriminative ability for the nomogram. The web-based clinicopathologic prediction models for predicting survival were based on Cox regression.
Results
The C-indexes for SYSUCC-A, SYSUCC-B, and WZRCH cohorts for the established nomograms to predict 3-year overall survival (OS) was 0.736, 0.715, and 0.691. Additionally, C-indexes to predict 3-year distant metastasis-free survival (DMFS) was 0.717, 0.706, and 0.686, disease-free survival (DFS) was 0.713, 0.697, and 0.656, local relapse-free survival was 0.695, 0.684, and 0.652, and regional relapse-free survival was 0.672, 0.650, and 0.616. The calibration plots showed great agreement between nomogram-predicted 3-year survival outcomes and actual 3-year survival outcomes. Moreover, C-indexes of the nomograms for OS, DMFS, and DFS were significantly superior than TNM stage (p< 0.001 for all).
Conclusion
These user-friendly nomograms can precisely predict survival endpoints in patients with non-metastatic NPC. They may serve as a useful tool for providing patient counseling and help physicians to make individual follow-up plans.

Citations

Citations to this article as recorded by  
  • A nomogram integrating clinical stage and pre-EBV DNA to identify the cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
    Sunqin Cai, Zongwei Huang, Zihan Chen, Ying Li, Jingjing Su, Ronghui Chen, Siqi Xu, Jing Wang, Sufang Qiu
    Radiation Oncology.2025;[Epub]     CrossRef
  • Adverse prognosis of nasopharyngeal carcinoma following long-term exposure to multiple air pollutants
    Xiao Lin, Yanan Jin, Jijin Yao, Xurui Sun, Tian Tian, Zhiqiang Li, Shimin Chen, Jie Jiang, Weihua Hu, Yuantao Hao, Liangping Xia, Wangjian Zhang
    Environmental Chemistry Letters.2024; 22(1): 21.     CrossRef
  • The development and external validation of a web-based nomogram for predicting overall survival with Ewing sarcoma in children
    Yi Chen, Zirui Liu, Yaobin Wang, Hongwei Zhan, Jinmin Liu, Yongkang Niu, Ao Yang, Fei Teng, Jinfeng Li, Bin Geng, Yayi Xia
    Journal of Children's Orthopaedics.2024; 18(2): 236.     CrossRef
  • The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis
    Ya-Nan Jin, Meng-Yun Qiang, Ying Wang, Yu-Jing Lin, Ren-Wei Jiang, Wan-Wei Cao, Wang-Jian Zhang, Si-Yang Wang, Hong-Yu Zhang, Ji-Jin Yao
    Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
  • Potential causal links of long‐term exposure to PM2.5 and its chemical components with the risk of nasopharyngeal carcinoma recurrence: A 10‐year cohort study in South China
    Xurui Sun, Xiao Lin, Jijin Yao, Tian Tian, Zhiqiang Li, Shimin Chen, Weihua Hu, Jie Jiang, Hui Tang, Huanle Cai, Tong Guo, Xudan Chen, Zhibing Chen, Man Zhang, Yongqing Sun, Shao Lin, Yanji Qu, Xinlei Deng, Ziqiang Lin, Liangping Xia, Yanan Jin, Wangjian
    International Journal of Cancer.2024; 155(9): 1558.     CrossRef
  • ALYREF promotes the metastasis of nasopharyngeal carcinoma by increasing the stability of NOTCH1 mRNA
    Yanan Jin, Jijin Yao, Jianchang Fu, Qitao Huang, Yilin Luo, Yafei You, Wangjian Zhang, Qian Zhong, Tianliang Xia, Liangping Xia
    Cell Death & Disease.2024;[Epub]     CrossRef
  • The continuous improvement of digital assistance in the radiation oncologist’s work: from web-based nomograms to the adoption of large-language models (LLMs). A systematic review by the young group of the Italian association of radiotherapy and clinical o
    Antonio Piras, Ilaria Morelli, Riccardo Ray Colciago, Luca Boldrini, Andrea D’Aviero, Francesca De Felice, Roberta Grassi, Giuseppe Carlo Iorio, Silvia Longo, Federico Mastroleo, Isacco Desideri, Viola Salvestrini
    La radiologia medica.2024; 129(11): 1720.     CrossRef
  • Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based on pre-treatment plasma EBV DNA
    Youliang Weng, Sunqin Cai, Chao Li, Yun Xu, Yuhui Pan, Zongwei Huang, Ying Li, Zijie Wu, Yu Chen, Sufang Qiu
    Scientific Reports.2024;[Epub]     CrossRef
  • A Nomogram for Predicting Recurrence in Stage I Non‐Small Cell Lung Cancer
    Rongrong Bian, Feng Zhao, Bo Peng, Jin Zhang, Qixing Mao, Lin Wang, Qiang Chen
    The Clinical Respiratory Journal.2024;[Epub]     CrossRef
  • Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response
    Yu‐Ting Jiang, Kai‐Hua Chen, Zhong‐Guo Liang, Jie Yang, Song Qu, Ling Li, Xiao‐Dong Zhu
    Cancer Medicine.2023; 12(4): 4010.     CrossRef
  • The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy
    Ji-Jin Yao, Ya-Nan Jin, Yu-Jing Lin, Wang-Jian Zhang, Tia Marks, Ian Ryan, Hong-Yu Zhang, Liang-Ping Xia
    Radiotherapy and Oncology.2023; 178: 109414.     CrossRef
  • Conditional survival nomogram for monitoring real-time survival of young non-metastatic nasopharyngeal cancer survivors
    Jianing Luo, Xiaonan Hu, Xiaofeng Ge
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10181.     CrossRef
  • Construction of Prognostic Nomogram in Patients with N3-Stage Nasopharyngeal Carcinoma
    Wenmiao Cao, Xiaoxin Li, Jianqi Yang, Enming Xing, Wenjuan Wu, Yizhi Ge, Buhai Wang
    ORL.2023; 85(4): 195.     CrossRef
  • Regional lymph node density-based nomogram predicts prognosis in nasopharyngeal carcinoma patients without distant metastases
    Jie Ma, Rong Zhao, Yu-Lan Wu, Yang Liu, Guan-Qiao Jin, Dan-Ke Su
    Cancer Imaging.2023;[Epub]     CrossRef
  • Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?
    Ya-Nan Jin, Hui-Jiao Cao, Xiao-Hua Gong, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
    Journal of Cancer Research and Clinical Oncology.2022; 148(10): 2569.     CrossRef
  • Development of a web-based prognostic model to quantify the survival benefit of cumulative cisplatin dose during concurrent chemoradiotherapy in childhood nasopharyngeal carcinoma
    Ya-Nan Jin, Qian-Qiong Yang, Zi-Qian Li, Xue-Qing Ou, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
    Radiotherapy and Oncology.2022; 166: 118.     CrossRef
  • A predictive web-based nomogram for the early death of patients with lung adenocarcinoma and bone metastasis: a population-based study
    Zhehong Li, Junqiang Wei, Haiying Cao, Mingze Song, Yafang Zhang, Yu Jin
    Journal of International Medical Research.2021;[Epub]     CrossRef
  • The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
    Jijin Yao, Ying Wang, Yujing Lin, Yingying Yang, Jingjing Wan, Xiaohua Gong, Fanwei Zhang, Wangjian Zhang, Tia Marks, Siyang Wang, Hongjun Jin, Hong Shan
    Drug Design, Development and Therapy.2021; Volume 15: 4157.     CrossRef
  • 8,661 View
  • 164 Download
  • 18 Web of Science
  • 18 Crossref
Close layer
Immunotherapy
The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
Si-Qi Tang, Ling-Long Tang, Yan-Ping Mao, Wen-Fei Li, Lei Chen, Yuan Zhang, Ying Guo, Qing Liu, Ying Sun, Cheng Xu, Jun Ma
Cancer Res Treat. 2021;53(2):339-354.   Published online November 6, 2020
DOI: https://doi.org/10.4143/crt.2020.790
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The occurrence pattern of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) in cancer treatment remains unclear.
Materials and Methods
Phase II-III clinical trials that evaluated ICI-based treatments in cancer and were published between January 2007 and December 2019 were retrieved from public electronic databases. The pooled median time to onset (PMT-O), resolution (PMT-R), and immune-modulation resolution (PMT-IMR) of irAEs were generated using the metamedian package of R software.
Results
Twenty-two eligible studies involving 23 clinical trials and 8,436 patients were included. The PMT-O of all-grade irAEs ranged from 2.2 to 14.8 weeks, with the longest in renal events. The PMT-O of grade ≥ 3 irAEs was significantly longer than that of all-grade irAEs induced by programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) inhibitors (27.5 weeks vs. 8.4 weeks, p < 0.001) and treatment of nivolumab (NIV) plus ipilimumab (IPI) (7.9 weeks vs. 6.0 weeks, p < 0.001). The PMT-R of all-grade irAEs ranged from 0.1 to 54.3 weeks, with the shortest and longest in hypersensitivity/infusion reaction and endocrine events, respectively. The PMT-IMR of grade ≥ 3 irAEs was significantly shorter than that of all-grade irAEs caused by PD-1/PD-L1 blockade (6.9 weeks vs. 40.6 weeks, p=0.002) and NIV+IPI treatment (3.1 weeks vs. 5.9 weeks, p=0.031).
Conclusion
This study revealed the general and specific occurrence pattern of ICI-induced irAEs in pan-cancers, which was deemed to aid the comprehensive understanding, timely detection, and effective management of ICI-induced irAEs.

Citations

Citations to this article as recorded by  
  • Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma
    Brooke Kielkowski, Diana Mansour, Brooke Ebbert, Kelsea Seago, Sijin Wen, Hang Li, Christine Barrett
    Journal of Oncology Pharmacy Practice.2026; 32(4): 608.     CrossRef
  • Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
    George Lau, Bruno Sangro, Ann-Lii Cheng, Masatoshi Kudo, Robin Kate Kelley, Won Young Tak, Antonio Gasbarrini, Maria Reig, Ho Yeong Lim, David Tougeron, Enrico N. De Toni, Vincent C. Tam, Kabir Mody, Jun Gong, Oxana V. Crysler, Wattana Sukeepaisarnjaroen,
    Hepatology.2026; 83(3): 484.     CrossRef
  • Successful Treatment of Aplastic Anemia Induced by Immune Checkpoint Inhibitors for Lung Cancer
    Chihiro Sumi, Masayo Yamamoto, Rena Sasaki, Takuya Funayama, Takeshi Saito, Mayumi Hatayama, Motohiro Shindo, Yasuhiro Umekage, Takaaki Sasaki, Sayaka Yuzawa, Mishie Tanino, Shuichiro Takahashi
    Internal Medicine.2026; 65(4): 562.     CrossRef
  • Decoding fatal toxic effects in checkpoint inhibitor therapy using real‐world pharmacovigilance data and machine learning
    Dongxue Yan, Beibei Lyu, Jie Yu, Siqi Bao, Zicheng Zhang, Meng Zhou, Jie Sun
    British Journal of Pharmacology.2026; 183(2): 364.     CrossRef
  • Neoadjuvant Immunotherapy
    Jay M. Lee
    Thoracic Surgery Clinics.2026; 36(1): 1.     CrossRef
  • Nebenwirkungen von Immuntherapien
    Fabian Bauer, Thorsten Persigehl
    Die Radiologie.2026; 66(1): 47.     CrossRef
  • Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy
    Dongxue Yan, Jingjing Xu, Dawei Wang, Qian Xing, Xinrong He, Donghao Wang, Biao zhu, Kaijiang Yu, Meng Zhou, Changsong Wang
    Molecular & Cellular Proteomics.2026; 25(1): 101488.     CrossRef
  • Guillain–Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study
    Jean Cabon, Mathilde Ducloie, Basile Chretien, Charlotte Arnaud, Joachim Alexandre, Charles Dolladille, Angélique Da Silva
    Journal of Neurology.2026;[Epub]     CrossRef
  • Tolerability of immune checkpoint inhibitors for cancer treatment in frail, older patients
    Rochelle Sheppard, Christopher Anstey, Leila Hanjani, Rahul Ladwa, Robin Berry, James Fletcher, Ruth Hubbard
    Journal of Geriatric Oncology.2026; 17(2): 102829.     CrossRef
  • Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma
    Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen
    Clinical Pharmacology & Therapeutics.2026; 119(4): 997.     CrossRef
  • Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials
    Wei-wu Chen, Shi-cheng Li, Qian Yin, Mei-ling Xu, Jun-jun Zhang, Xiang-rong Zhao, Peng-fei Xing, Yue-hong Kong, Li-yuan Zhang
    Cancer Immunology, Immunotherapy.2026;[Epub]     CrossRef
  • Usability and Acceptance Testing of an Electronic Patient-Reported Outcome Symptom Monitoring System for People Receiving Immune Checkpoint Inhibitors: Mixed Methods Study
    Julia Lai-Kwon, Claudia Rutherford, Stephanie Best, Hasan Shahid Ferdous, Iris Zhang, Thai-Khoa Ly, Dishan Herath, Kate Burbury, Michael Jefford
    JMIR Formative Research.2026; 10: e79694.     CrossRef
  • Adverse drug reaction assessment of pembrolizumab and nivolumab in esophageal cancer treatment based on the US FAERS database
    Jinhan Chen, Qian Xu, Yuou Ying, Jinsheng Yu, Yi Liu, Fangmin Zhao, Qijin Shu
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • A Case of Fulminant Immune‐Related Enterocolitis During Immune Checkpoint Inhibitor Therapy for Metastatic Renal Cell Carcinoma
    Kasumi Kanai, Takayuki Sumiyoshi, Hiroki Kitamoto, Yuki Teramoto, Yuta Mine, Jin Kono, Kimihiko Masui, Takayuki Goto, Ryoichi Saito, Takashi Kobayashi
    IJU Case Reports.2026;[Epub]     CrossRef
  • Fatal AA-like bone marrow failure and invasive pulmonary aspergillosis after long-term pembrolizumab in squamous NSCLC: a case report
    Yawen Wang, Weigang Dong, Jianwen Qin
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Comparison of pembrolizumab dosing regimens and incidence and severity of immune-related adverse effects: A retrospective, case-control study
    Taylor E Monson, Vincent J Cascone, Francisco J Diaz, Junqiang Dai, Gary C Doolittle
    American Journal of Health-System Pharmacy.2026;[Epub]     CrossRef
  • Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis
    Yu Bai, Hong Liu, Hao Meng
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • A Multidisciplinary Approach to Checkpoint Inhibitor Adverse Reactions
    Courtney N. Andrews, Eric M. Mukherjee, Andrew Gibson, Michael A. Postow, Elizabeth J. Phillips, Douglas B. Johnson
    The Journal of Allergy and Clinical Immunology: In Practice.2026; 14(5): 1058.     CrossRef
  • Mouse models of immune-related adverse events: progress, challenges, and opportunities
    Theodoros Papadopoulos, Ariel Pinto, Madelyn J. Abraham, Carolina L. Naranjo, Manuel F. Molina, Marie Hudson, Wilson H. Miller, Sonia V. Del Rincón
    Trends in Cancer.2026;[Epub]     CrossRef
  • Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy
    Yao Qiu, Xincai Zhao, Juan Chen, Manman Zhang, Yonggang Wang, Cheng Guo, Jianping Zhang, Rong Xu
    Frontiers in Oncology.2026;[Epub]     CrossRef
  • Immune checkpoint inhibitor-associated hepatitis and colitis: current understanding and clinical approaches
    Yuta Myojin, Takahiro Kodama
    Immunological Medicine.2026; : 1.     CrossRef
  • Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study
    Wenfang Jin, Ying Zhao, Yanling Lv, Yu Yao, Xin Su
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Intensive care admissions for severe immune-related adverse events associated with immune checkpoint inhibitor therapy: a 10-year cohort study
    Samuel Pichon, Ghadi Zebian, Charlotte Lacombe, Alexandre Mole, Lidwine Wemeau, Emmanuel Ledoult, Ahmed E.L. Kalioubie, Alexandre Gaudet, Laurent Robriquet, Côme Bureau, David Launay, Clémentine Levy, Vincent Sobanski, Mercedes Jourdain
    Journal of Critical Care.2026; 95: 155655.     CrossRef
  • Immune‑related nephritis, ureteritis and cystitis secondary to immune checkpoint inhibitors: A case report and review of the literature
    Guangquan Zhang, Silu Xu, Jing Wu, Qianqian Gao, Yanzhi Bi, Min Xiao
    Experimental and Therapeutic Medicine.2026; 32(2): 1.     CrossRef
  • Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer
    Khoudia Diop, Myriam Benlaïfaoui, Sébastien Hunter, Eder Orlando Méndez-Salazar, Taiki Hakozaki, Corentin Richard, Diogjena Katerina Prifti, Sylva Kourtian, Francis Proulx-Rocray, Sabrine Naimi, Mayra Ponce, Meriem Messaoudene, Florent Cauchois, Wiam Belk
    Microbiome.2026;[Epub]     CrossRef
  • Machine learning-based models for predicting the efficacy and safety of recombinant human interleukin-11 in the treatment of cancer therapy-induced thrombocytopenia: exploration and preliminary validation from a multicenter retrospective study
    Yingmei Wen, Jinxiong Xia, Yi Dong, Zheming Liu, Shuyang Yu, Yuanyuan Wang, Shuman Qing, Xinyi Li, Jingyi Miao, Dongling Tang, Yi Yao
    Frontiers in Cell and Developmental Biology.2026;[Epub]     CrossRef
  • Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients
    Taras Lyubchenko, Evgeny Berdyshev, Ryan M. Weight, Olivia Xiao, Neil J. Shah, Alina Markova, Mario E. Lacouture, Jeffrey A. Kern, Elena Goleva, Donald Y. M. Leung
    Allergy.2026;[Epub]     CrossRef
  • Oral and cutaneous immune‐related adverse events in cancer patients: Prevalence and overall survival
    Osias Vieira de Oliveira Filho, Ivana Lameiras Gibbons, Yuri de Lima Medeiros, Thiago Bueno de Oliveira, Nathaniel Simon Treister, Fabio Abreu Alves
    Oral Diseases.2025; 31(1): 278.     CrossRef
  • Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite Instability-High Metastatic Colorectal Cancer
    Annie Xiao, Xiaochen Li, Chongkai Wang, Marwan Fakih
    Clinical Colorectal Cancer.2025; 24(1): 32.     CrossRef
  • Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system
    Naoto Okada, Tomoyuki Yanagi, Takaaki Sasaki, Miho Tamura, Masakazu Ozaki, Atsuyuki Saisyo, Takashi Kitahara
    International Journal of Cancer.2025; 156(2): 293.     CrossRef
  • Olmesartan-associated Gastritis Observed Over Time
    Mizuho Fujisawa, Tetsuya Yoshizaki, Satoshi Urakami, Risa Ashizaki, Eri Nishikawa, Hiroshi Tanabe, Shinya Hoki, Ryosuke Ishida, Hitomi Hori, Chise Ueda, Hirofumi Abe, Madoka Takao, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama
    Internal Medicine.2025; 64(12): 1843.     CrossRef
  • Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer
    Cynthia X. Wei, Sandra K. Althouse, Hirva Mamdani, Nasser H. Hanna, Greg A. Durm
    Clinical Lung Cancer.2025; 26(3): e154.     CrossRef
  • The use of peripheral blood biomarkers for predicting the risk of immune-related adverse events in immune checkpoint inhibitor therapy
    Louise E Duvall
    Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2025; 62(4): 236.     CrossRef
  • Developing alert thresholds and self-management advice for people receiving immune checkpoint inhibitors: a Multinational Association for Supportive Care in Cancer modified Delphi survey
    Julia Lai-Kwon, Claudia Rutherford, Stephanie Best, Hope S. Rugo, Christina H. Ruhlmann, Michael Jefford
    Supportive Care in Cancer.2025;[Epub]     CrossRef
  • Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer
    Leila-Sophie Otten, Alessandra I. G. Buma, Berber Piet, Rob ter Heine, Michel M. van den Heuvel, Valesca P. Retèl
    PharmacoEconomics - Open.2025; 9(3): 471.     CrossRef
  • Clinical and economic impact of the advanced practice nurse in lung cancer patients receiving immunotherapy-based treatments: A quantitative study
    Jorgina Serra-López, Clara Pujol-Besora, Sergio Martínez-Recio, Andrés Barba, Mariona Riudavets Melià, Ivana Sullivan, Jordi Torralbas-Ortega, Gina Lladó-Jordan, Margarita Majem, Maria-Antonia Martínez-Momblan
    European Journal of Oncology Nursing.2025; 74: 102809.     CrossRef
  • Long-term immune related adverse events
    Leo Plaçais, Olivier Lambotte
    Current Opinion in Oncology.2025; 37(2): 142.     CrossRef
  • Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study
    Jonas Paul Wiegmann, Tabea Fröhlich, Nora Möhn, Laura Duzzi, Emily Narten, Johanna Aurich, Janin Thomas, Lea Grote‐Levi, Susann Mahjoub, Dominik Berliner, Thomas Wirth, Heiko Golpon, Benjamin‐Alexander Bollmann, Imke Von Wasilewski, Ralf Gutzmer, Florian
    Cancer Medicine.2025;[Epub]     CrossRef
  • Application of Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma: Current Status, Challenges, and Future Directions
    Lingxiang Ran, Rui Zhao, Yu Li, Benfan Lin, Zhen Yang, Yuanyin Teng, Jingyi Li, Shi Wang, Hsu Yi Liang, Guangmo Hu
    AI Med.2025; 1(1): 1.     CrossRef
  • Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
    Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Xingyu Wei, Fei Li, Dehua Liao
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Challenges and opportunities in single-domain antibody-based tumor immunotherapy
    Xiaozhi Xi, Shasha Guo, Yuchao Gu, Xuekai Wang, Qiang Wang
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2025; 1880(2): 189284.     CrossRef
  • Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis
    Qimei Fang, Yan Qian, Zhaolu Xie, Hongqiong Zhao, Yang Zheng, Di Li
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Clinical Characteristics of Toxicities of Immune Checkpoint Inhibitors and Their Impact on Efficacy in Solid Cancers: An Analysis of Real-World Data in Moroccan Patients
    Badiaa Batlamous, Sihame Lkhoyaali, Loubna Omri, Magaly-Gwen-Farnely Nguema-Mipaka, Mohamed Khalis, Hanane Inrhaoun, Sarah Naciri, Ibrahim El Ghissassi, Hind Mrabti, Saber Boutayeb, Hassan Errihani
    JCO Global Oncology.2025;[Epub]     CrossRef
  • Late-onset bone granulomatous reaction of hand from immune checkpoint-inhibitors detected on FDG-PET/CT
    Miki Nishimori, Kouki Togami, Noriko Nitta, Kana Miyatake, Hitomi Iwasa, Kosuke Nakaji, Kenta Ogi, Takayasu Izumi, Tomohiro Matsumoto, Rika Yoshimatsu, Tomoaki Yamanishi, Kazufumi Takamatsu, Shudai Muramatsu, Mayuko Yamamoto, Takuji Yamagami
    Radiology Case Reports.2025; 20(5): 2338.     CrossRef
  • Treatment Selection for Patients with HER2-Negative Metastatic Gastric Cancer Expressing Claudin 18.2 and PD-L1
    Yusuke Miyajima, Takeshi Kawakami
    Cancers.2025; 17(7): 1120.     CrossRef
  • Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the FAERS database
    Huiping Zhang, Zhuo Zhou, Juan Wang, Shan Wang, Jie Ren, Ming Zhang, Mingyi Yang
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Autoimmune-related adverse events induced by immune checkpoint inhibitors
    Yuanqiang Sun, Ziyang Zhang, Ke Jia, Hong Liu, Furen Zhang
    Current Opinion in Immunology.2025; 94: 102556.     CrossRef
  • Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors
    Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Pranav M. Patel, Yoshito Zamami, Aya F. Ozaki
    Cardio-Oncology.2025;[Epub]     CrossRef
  • Three-year analysis of the Belgian multidisciplinary immunotoxicity (BITOX) board: organization, feasibility, and results
    M. Verhaert, Y. Aydogan, S. Aspeslagh
    ESMO Real World Data and Digital Oncology.2025; 8: 100147.     CrossRef
  • Lung cancer with diabetes mellitus and polymyalgia rheumatica during long‑term nivolumab treatment: A case report
    Makoto Nakao, Ayami Hirano, Masato Nakai, Syuntaro Hayashi, Mamiko Kuriyama, Norihisa Takeda, Hideki Muramatsu
    Experimental and Therapeutic Medicine.2025; 29(6): 1.     CrossRef
  • Immune checkpoint inhibitors: From friend to foe
    Prem Rajak
    Toxicology Reports.2025; 14: 102033.     CrossRef
  • Systemic immune characteristics predicting toxicity to immune checkpoint inhibitors in patients with advanced breast cancer
    Yalong Qi, Hewei Ge, Xiaoying Sun, Yuhan Wei, Jingtong Zhai, Haili Qian, Hongnan Mo, Fei Ma
    Journal of Autoimmunity.2025; 153: 103423.     CrossRef
  • Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma
    Sarit E. Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B. Johnston, Alexey V. Danilov, Brenda W. Cooper, Aleksander Chudnovsky, Junyu Ding, Tao Long, Dina Stroopinsky, Deborah Berg, Lapo Alinari
    Clinical Lymphoma Myeloma and Leukemia.2025; 25(11): 788.     CrossRef
  • Dynamic variations in peripheral blood indices and their association with efficacy and adverse reactions of pd- 1 inhibitor combined chemotherapy in patients with advanced gastric cancer
    Rui Wang, Huihui Zeng, Mengting Shi, Yue Wu, Yang Liu, Tiantian Zhang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study
    Takahito Sugase, Takashi Kanemura, Norihiro Matsuura, Tomohira Takeoka, Yuki Ushimaru, Yasunori Masuike, Yoshitomo Yanagimoto, Kazuyoshi Yamamoto, Takeshi Omori, Ryota Mori, Masatoshi Kitakaze, Masahiko Kubo, Yosuke Mukai, Hisateru Komatsu, Toshinori Sued
    Esophagus.2025; 22(4): 565.     CrossRef
  • Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
    Claire Morgan, John Kurland, Mayur Patel, Cathy O’Brien, Pamela Concepcion, Gary J Doherty, Stephan Hois, Alejandra Negro, Dejan Pavlovic, Karen A Robbins
    Journal for ImmunoTherapy of Cancer.2025; 13(5): e011140.     CrossRef
  • Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study
    Anna Olsson-Brown, Ankit Jain, Ricky Frazer, David Farrugia, Judith Carser, John Houghton, Ruth D. Lewis, Simon D’Mello, Gabrielle Emanuel
    Oncology and Therapy.2025; 13(3): 649.     CrossRef
  • Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan
    Hiroki Nishikawa, Soo Ki Kim, Akira Asai
    Journal of Clinical Medicine.2025; 14(13): 4514.     CrossRef
  • A novel carrier-free nanoparticle with stable distinctive three-dimensional structure for tumor-targeted precision chemoimmunotherapy
    Bo Deng, Youpeng Kong, Yingying Ma, Yijie Zhan, Yitong Sun, Rudan Wang, Pengyu Huang, Lanxia Liu
    Journal of Nanobiotechnology.2025;[Epub]     CrossRef
  • The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events
    Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdu, Zhengrui Li, Jian Zhang, Peng Luo
    Med Research.2025; 1(3): 322.     CrossRef
  • A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
    Breelyn A. Wilky, Katherine A. Julian, Alessandra Maleddu, Anne C. Mailhot, Chelsey R. Cartwright, Dexiang Gao, Cristiam Moreno Tellez, Lindsey E. Kemp, Nicholas R. Therrien, Sumra S. Chaudhry, Jeffrey D. Rytlewski, Qierra R. Brockman, Eduardo Davila, Ant
    Clinical Cancer Research.2025; 31(14): 2945.     CrossRef
  • Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis
    Jay M. Lee, Alessandro Brunelli, Amy L. Cummings, Enriqueta Felip, Catherine A. Shu, Benjamin J. Solomon, Masahiro Tsuboi, Heather Wakelee, Anjali Saqi, Yi-Long Wu, Pao-Chen Li, Barbara J. Gitlitz
    JTO Clinical and Research Reports.2025; 6(9): 100866.     CrossRef
  • Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)
    Shanshan Xu, Zhihui Song, Dong Wang, Ente Wang, Jiawei Wang
    BMC Cancer.2025;[Epub]     CrossRef
  • Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma
    Akihiro Miyashita, Taichi Murao, Yuji Shimura, Haruya Okamoto, Hiroaki Nagata, Akio Onishi, Takahiro Fujino, Shinsuke Mizutani, Taku Tsukamoto, Junya Kuroda
    Cureus.2025;[Epub]     CrossRef
  • Nivolumab-Induced Refractory Hemorrhagic Gastritis and Duodenitis Requiring Multimodal Biologic Therapy
    Roney Shibu, Kayla Scully, Waled Mohsen, Robert Mason, Sooraj Rajendran Pillai
    ACG Case Reports Journal.2025; 12(8): e01782.     CrossRef
  • Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab
    Hifaa Al Remawi, Maria Lindén, Zhiyuan Zhao, Ankur Pandita, Anna Rudin, Lars Ny, Sara Bjursten, Max Levin
    OncoImmunology.2025;[Epub]     CrossRef
  • Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma
    Piotr Kawczak, Igor Jarosław Feszak, Tomasz Bączek
    Cancers.2025; 17(17): 2805.     CrossRef
  • Diagnosis and treatment of a patient with severe hepatitis and rash caused by toripalimab: A case report
    Wei Guo, Yurun Li, Jing Li, Liping Dai, Yuting Jia, Ting Jiang
    Medicine.2025; 104(35): e44122.     CrossRef
  • A Guide for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Induced Liver Injury
    Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Sadahisa Ogasawara, Yuzo Kodama, Mina Komuta, Kenichi Harada, Naoya Sakamoto, Atsushi Tanak
    Kanzo.2025; 66(9): 375.     CrossRef
  • Association Between Immune‐Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study
    Kazumasa Yamamoto, Hidekazu Hirano, Toshiharu Hirose, Hirokazu Shoji, Natsuko Okita, Atsuo Takashima, Ken Kato
    Cancer Medicine.2025;[Epub]     CrossRef
  • Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study
    Yuan Cheng, Jun-Ying Wang, You Lu, Yong-Xiang Xia, Hui Zhao, Qi Wang, Xiao-Li Zhu, Qing-Quan Zu, Hui-Kai Li, Zhong Chen, Xiang-Cheng Li
    Hepatobiliary & Pancreatic Diseases International.2025; 24(6): 656.     CrossRef
  • Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database
    Lingli Huang, Haitian Wang, Nan Wu
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade
    Romain Guitton, Ariane Laparra, Noemie Chanson, Stephane Champiat, Francois-Xavier Danlos, Jean-Marie Michot, Sabine Messayke, Aurelien Marabelle, Olivier Lambotte
    Journal for ImmunoTherapy of Cancer.2025; 13(9): e012756.     CrossRef
  • Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review
    Toshali Pandey, Sajjad A. Bhatti
    Cancer Immunology, Immunotherapy.2025;[Epub]     CrossRef
  • A study on adverse drug events of PD-1/PD-L1 inhibitors in lung cancer treatment: a decade-long data mining
    Chenglin Jia, Yukai Lai, Zhuo Wang, Wei He, Xuan Huang, Xiaoyan Yang
    Scientific Reports.2025;[Epub]     CrossRef
  • Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study
    Moti N. Ramgopal, Jacob P. Lalezari, Ana Gabriela Pires dos Santos, Preethi Krishnan, Tanaya R. Vaidya, Fei Zhou, Heide Betman, Patrick Dorr, Nael M. Mostafa, Maria L. Alcaide, Franco Felizarta, Jean-Pierre Routy
    Nature Medicine.2025; 31(11): 3879.     CrossRef
  • Isolated Adrenocorticotropic Hormone Deficiency during Preoperative Chemotherapy with Pembrolizumab—A Case Report—
    Chika SANADA, Kensuke KAWASAKI
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2025; 86(4): 489.     CrossRef
  • Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)
    Nabil E. Omar, Shereen Elazzazy, Anas Hamad, Mohamed Omar Saad, Aya Alasmar, Sahar M. Nasser, Maria Benkhadra, Hebatalla M. Afifi, Farah I. Jibril, Rawan A. Dawoud, Mohamed S. Hamid, Afnan Alnajjar, Arwa O. Sahal, Amaal Gulied, Hazem Elewa
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors
    Nicola Marrano, Mariangela Caporusso, Carlo Ganini, Andrea Borraccino, Angelo Cignarelli, Sebastio Perrini, Luigi Laviola, Camillo Porta, Francesco Giorgino, Annalisa Natalicchio
    Journal of Endocrinological Investigation.2025; 49(2): 399.     CrossRef
  • Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer
    Saya Jacob, Samantha Fisch, Carolyne Face, Kelly Blum, Madhuri Chengappa, Saliha Chaudhry, Alexis LeVee, Nikita V. Baclig, Andrew Soliman, Laura A. Huppert, Zoe Quandt, Laura Quintal, Dame Idossa, Michelle Melisko, A. Jo Chien, Mi-Ok Kim, Joanne Mortimer,
    npj Breast Cancer.2025;[Epub]     CrossRef
  • Adverse Event Monitoring with Imaging: Prognostic Significance in Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma
    Jeayeon Park, Dong Ho Lee, Yunmi Ko, Hyunjae Shin, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon, Su Jong Yu
    Liver Cancer.2025; 15(3): 439.     CrossRef
  • Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies
    Akmal Zubair, Safa Wdidi
    Discover Oncology.2025;[Epub]     CrossRef
  • ChronoimmunoTOX: A Single-Institution Retrospective Study on How the Time of Administration Impacts Immune Checkpoint Inhibitor Efficacy and Toxicity in Melanoma
    Alessandro Nepote, Gilles Burghgraeve, Martino Pedrani, Anderson Junior Gomez Ramos, Isabella Saporita, Vito Spataro, Vittoria Espeli, Ricardo Pereira Mestre, Dario Sangiolo, Martina Imbimbo, Cristina Mangas
    Journal of Clinical Medicine.2025; 15(1): 69.     CrossRef
  • Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review
    Guangqiang Hu, Zeng Li, Yongji Chen, Hong Liao, Shukui Zhou
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • A Case of Unresectable Advanced Esophageal Cancer with Recurrent Pneumatosis Intestinalis and Portal Venous Gas during Chemotherapy with Immune Checkpoint Inhibitors
    Hiroki Tashiro, Takafumi Suzuki, Hironori Tsujimoto, Seiichiro Fujishima, Hanae Shinada, Risa Kariya, Naoyuki Uehata, Asuma Ide, Keita Kouzu, Hiroyuki Horiguchi, Yoshihisa Yaguchi, Kaya Ijiri, Kosuke Miyai, Susumu Matsukuma, Hideki Ueno
    Surgical Case Reports.2025; 11(1): n/a.     CrossRef
  • Immune checkpoint inhibitor–related adverse events: Real-world experience from a single veterans’ affairs medical center
    Samantha Benz, Katherine A Sherman, Constantin A Dasanu, Juliana Alvarez-Argote
    Journal of Oncology Pharmacy Practice.2024; 30(4): 697.     CrossRef
  • Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors
    Kremena Petrova Trichkova, Franziska Görtler, Line Bjørge, Cornelia Schuster
    Cancers.2024; 16(2): 250.     CrossRef
  • Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
    Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía,
    Gastroenterología y Hepatología.2024; 47(4): 401.     CrossRef
  • Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
    Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandí
    Revista Española de Enfermedades Digestivas.2024;[Epub]     CrossRef
  • Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis
    Sangwon Shin, Jimin Moon, Chiyoon Oum, Seulki Kim, Soo Ick Cho, Yoojoo Lim, Chan-Young Ock, Seunghwan Shin
    BMC Cancer.2024;[Epub]     CrossRef
  • A case of Stiff-person syndrome with muscle tonicity of the extremities and neck after use of Dulvalumab for lung adenocarcinoma
    Takashi Inoue, Kei Oiwa, Kazuhiro Horiuchi
    Rinsho Shinkeigaku.2024; 64(3): 176.     CrossRef
  • Clinical and translational attributes of immune-related adverse events
    Karijn P. M. Suijkerbuijk, Mick J. M. van Eijs, Femke van Wijk, Alexander M. M. Eggermont
    Nature Cancer.2024; 5(4): 557.     CrossRef
  • Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach
    Desirèe Speranza, Mariacarmela Santarpia, Francesco Luppino, Fausto Omero, Enrica Maiorana, Mariacarmela Cavaleri, Elena Sapuppo, Vincenzo Cianci, Alessia Pugliese, Vito Racanelli, Giulia Maria Camerino, Carmelo Rodolico, Nicola Silvestris
    Expert Opinion on Drug Safety.2024; 23(11): 1405.     CrossRef
  • Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation
    Arielle Elkrief, Nicholas R. Waters, Natalie Smith, Angel Dai, John Slingerland, Nathan Aleynick, Binita Febles, Pooja Gogia, Nicholas D. Socci, Melissa Lumish, Paul A. Giardina, Jamie E. Chaft, Juliana Eng, Robert J. Motzer, Robin B. Mendelsohn, Kate A.
    Cancer Immunology Research.2024; 12(3): 308.     CrossRef
  • Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
    Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía,
    Gastroenterología y Hepatología (English Edition).2024; 47(4): 401.     CrossRef
  • Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity
    静宜 任
    Advances in Clinical Medicine.2024; 14(03): 284.     CrossRef
  • Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients
    Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, David Balakirouchenane, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Marie-Claire Bretagne, Joe-Elie Salem, Xavier Declèves, Michel Vidal, Nora Kramkimel, Sarah Guegan, Selim Aractingi, Olivier Hui
    British Journal of Cancer.2024; 130(11): 1866.     CrossRef
  • Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian S
    Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Mon
    Cancer Treatment Reviews.2024; 126: 102734.     CrossRef
  • Guide for the Diagnosis of Immune Checkpoint Inhibitor-Induced Liver Injury
    Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka
    Kanzo.2024; 65(6): 268.     CrossRef
  • Diagnostic guide for immune checkpoint inhibitor‐induced liver injury
    Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka
    Hepatology Research.2024; 54(8): 719.     CrossRef
  • Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms?
    Mohamed Mahmoud El-Sayed, Julia Raffaella Bianco, YiJing Li, Zsolt Fabian
    Cells.2024; 13(12): 1071.     CrossRef
  • Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient with Larnyngeal Cancer
    O Karhan, Y Sezgin, S Ileri, S Tunc
    Nigerian Journal of Clinical Practice.2024; 27(6): 800.     CrossRef
  • Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis
    Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, T
    Cancer Medicine.2024;[Epub]     CrossRef
  • Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
    Guihong Wan, Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan, Ahmad Rajeh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Matthew J Hadfield, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R LeBoeuf, Kerry L Reynolds,
    The Lancet Oncology.2024; 25(8): 1053.     CrossRef
  • Selecting Immune Checkpoint Inhibitor Side Effects for Real-Time Monitoring in Routine Cancer Care: A Modified Delphi Study
    Julia Lai-Kwon, Michael Jefford, Stephanie Best, Iris Zhang, Claudia Rutherford
    JCO Oncology Practice.2024; 20(12): 1663.     CrossRef
  • Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis
    Stephanie van der Leij, Karijn P.M. Suijkerbuijk, Medard F.M. van den Broek, Gerlof D. Valk, Jan Willem Dankbaar, Hanneke M. van Santen
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action
    Antonio Malvaso, Pierpaolo Giglio, Luca Diamanti, Matteo Gastaldi, Elisa Vegezzi, Andrea Pace, Paola Bini, Enrico Marchioni
    Brain Sciences.2024; 14(8): 764.     CrossRef
  • Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy
    Gerald J. Sun, Gustavo Arango-Argoty, Gary J. Doherty, Damian E. Bikiel, Dejan Pavlovic, Allen C. Chen, Ross A. Stewart, Zhongwu Lai, Etai Jacob
    iScience.2024; 27(9): 110634.     CrossRef
  • Toxicity in the era of immune checkpoint inhibitor therapy
    Synat Keam, Naimah Turner, Fernanda G. Kugeratski, Rene Rico, Jocelynn Colunga-Minutti, Rayansh Poojary, Sayan Alekseev, Anisha B. Patel, Yuanteng Jeff Li, Ajay Sheshadri, Monica E. Loghin, Karin Woodman, Ashley E. Aaroe, Sarah Hamidi, Priyanka Chandrasek
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors
    Christopher J. Hoimes, Suzanne McGettigan, Lee Schwartzberg
    The American Journal of Medicine.2024; 137(12): 1200.     CrossRef
  • Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study
    Mari Yokoi, Atsushi Yonezawa, Daiki Hira, Tomohiro Handa, Kiminobu Tanizawa, Shunsaku Nakagawa, Masahiro Tsuda, Yasuaki Ikemi, Ryo Itotani, Hironori Yoshida, Motoo Nomura, Junichi Matsubara, Kosaku Murakami, Hiroaki Ozasa, Manabu Muto, Tomohiro Terada
    Journal of Pharmaceutical Health Care and Sciences.2024;[Epub]     CrossRef
  • Melittin-incorporated nanomedicines for enhanced cancer immunotherapy
    Xuefeng Duan, Haoyang Zou, Jiazhen Yang, Shixian Liu, Tianmin Xu, Jianxun Ding
    Journal of Controlled Release.2024; 375: 285.     CrossRef
  • Do corticosteroids affect immunotherapy efficacy in malignancy? – A systematic review
    Yoni Byron, Sonya Yegorova‐Lee, Martin Tio
    Cancer Medicine.2024;[Epub]     CrossRef
  • Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver
    Luca Marzi, Andrea Mega, Chiara Turri, Stefano Gitto, Federica Ferro, Gilbert Spizzo
    International Journal of Molecular Sciences.2024; 25(21): 11676.     CrossRef
  • Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy
    Iris Teruel, Eva Castellà, Sabela Recalde, Gemma Viñas, Anna Petit, Macedonia Trigueros, Eva Martínez-Balibrea, Eudald Felip, Milana Bergamino, Adrià Bernat-Peguera, Beatriz Cirauqui, Vanesa Quiroga, Angelica Ferrando-Díez, Anna Pous, Assumpció López, Lai
    International Journal of Molecular Sciences.2024; 25(22): 12241.     CrossRef
  • The effects of anti-PD-1 therapy on programmed death-ligand 1 expression and glucose metabolism of normal organs in patients with advanced non-small cell lung cancer
    Matthew Severyn, Eunice H L Lee, Gitasha Chand, Jessica Johnson, Damion Bailey, Kathryn Adamson, Vicky Goh, Daniel Johnathan Hughes, Gary J R Cook
    BJR|Open.2024;[Epub]     CrossRef
  • Safety of sequential immune checkpoint inhibitors after prior immune therapy
    Muhammad Awidi, Brendan Connell, Delaney Johnson, Isabel Craven, Rojer Ranjit, Brigitte Gil, Natalie Dal’Bo, Lewena Maher, Seanna Reilly Daves, Stephanie McDonald, Krishna S. Gunturu
    Journal of Cancer Research and Clinical Oncology.2023; 149(6): 2375.     CrossRef
  • The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex
    Murielle N. Wahli, Stefanie Hayoz, Dennis Hoch, Christoph O. Ryser, Michèle Hoffmann, Amina Scherz, Birgit Schwacha-Eipper, Simon Häfliger, Julian Wampfler, Martin D. Berger, Urban Novak, Berna C. Özdemir
    Journal of Cancer Research and Clinical Oncology.2023; 149(7): 3847.     CrossRef
  • Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy
    Atsushi Yamaguchi, Yoshitaka Saito, Katsuya Narumi, Ayako Furugen, Yoh Takekuma, Naofumi Shinagawa, Yasushi Shimizu, Hirotoshi Dosaka-Akita, Mitsuru Sugawara, Masaki Kobayashi
    Journal of Cancer Research and Clinical Oncology.2023; 149(4): 1659.     CrossRef
  • Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large‐scale pharmacovigilance analysis
    Qian Guo, Jian Gao, Hui Guo, Jun Xie, Jingmin Cheng
    International Immunopharmacology.2023; 114: 109490.     CrossRef
  • Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis
    Su Jeong Song, Yun-Kyoung Song, Mihwa Jang, Eunjeong Shin, Sung Yun Suh, Yoon Sook Cho, Ju-Yeun Lee, Jung Mi Oh
    Targeted Oncology.2023; 18(1): 147.     CrossRef
  • Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis
    Qian Guo, Jin Ning Zhao, Ting Liu, Jian Gao, Hui Guo, Jing Min Cheng
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
    Deniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, Gozde Kavgaci, Melek Seren Aksun, Enes Erul, Hasan Cagri Yildirim, Elvin Chalabiyev, Cebrayil Cebroyilov, Tolga Yildirim, Omer Dizdar, Sercan Aksoy, Suayib Yalcin, Saadettin Kilickap, Mustafa Erman, Mus
    Anti-Cancer Drugs.2023; 34(6): 783.     CrossRef
  • Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
    Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony S. K. Mok, Martin Reck, Gene G. Finley, Monika D. Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bāra, Howard J. West
    JAMA Oncology.2023; 9(4): 527.     CrossRef
  • Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment
    Gaetano Maria Russo, Anna Russo, Fabrizio Urraro, Fabrizio Cioce, Luigi Gallo, Maria Paola Belfiore, Angelo Sangiovanni, Stefania Napolitano, Teresa Troiani, Pasquale Verolino, Antonello Sica, Gabriella Brancaccio, Giulia Briatico, Valerio Nardone, Alfons
    Diagnostics.2023; 13(4): 793.     CrossRef
  • Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
    Juyue Zhou, Zhonghai Du, Jie Fu, Xiuxiu Yi
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report
    Nidhi Goel, Monica D. Levine, Laura M. Chambers, Christa I. Nagel
    Gynecologic Oncology Reports.2023; 47: 101174.     CrossRef
  • Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
    Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner
    Journal for ImmunoTherapy of Cancer.2023; 11(3): e006398.     CrossRef
  • Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients
    Berna C. Özdemir, Cristina Espinosa da Silva, Dimitri Arangalage, Pierre Monney, Sabina A. Guler, Uyen Huynh-Do, Guido Stirnimann, Lucia Possamai, Roman Trepp, Robert Hoepner, Anke Salmen, Camille L. Gerard, Petr Hruz, Lisa Christ, Sacha I. Rothschild
    Cancer Immunology, Immunotherapy.2023; 72(7): 1991.     CrossRef
  • Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features
    Julianna Martel, Hannah L. Hanania, Anisha B. Patel
    Human Pathology.2023; 140: 144.     CrossRef
  • Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity
    Catherine C. Fahey, Thomas J. Gracie, Douglas B. Johnson
    Expert Review of Anticancer Therapy.2023; 23(7): 673.     CrossRef
  • Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
    Rafael Morales-Barrera, Guillermo Villacampa, Natalia Vidal, Mariona Figols, Julia Giner, Teresa Bonfill, Cristina Suárez, Nely Díaz, Joaquín Mateo, Macarena González, Montserrat Domenech, Javier Puente, Joan Carles
    Clinical and Translational Oncology.2023; 25(12): 3556.     CrossRef
  • The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review
    Julia Lai-Kwon, Jordan E. Cohen, Karolina Lisy, Claudia Rutherford, Afaf Girgis, Ethan Basch, Michael Jefford
    JCO Clinical Cancer Informatics.2023;[Epub]     CrossRef
  • Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma
    Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, Hiroki Kubota, Yusuke Noda, Maria Aoki, Yoshinobu Moritoki, Satoshi Nozaki, Satoshi Kurokawa, At
    International Journal of Urology.2023; 30(10): 866.     CrossRef
  • Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy
    Shu-Jung Hsu, Yen-Cheng Chao, Xia-Hui Lin, Hua-Hua Liu, Yang Zhang, Wei-Feng Hong, Mao-Pei Chen, Xin Xu, Lan Zhang, Zheng-Gang Ren, Shi-Suo Du, Rong-Xin Chen
    Clinical and Experimental Immunology.2023; 212(3): 239.     CrossRef
  • First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
    Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Tarek M. Meniawy, Michele Del Vecchio, Céleste Lebbé, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stéphane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen B
    Journal of Clinical Oncology.2023; 41(23): 3917.     CrossRef
  • Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between
    Hyo Sook Han, Praveen Vikas, Ricardo L.B. Costa, Nusrat Jahan, Ammanuel Taye, Erica M. Stringer-Reasor
    American Society of Clinical Oncology Educational Book.2023;[Epub]     CrossRef
  • An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management
    Yiyu Cheng, Fangmei Ling, Junrong Li, Yidong Chen, Mingyang Xu, Shuang Li, Liangru Zhu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma
    Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Tetsuya Tsuchida, Ai Yoshida, Takako Yamada, Akira Komoto
    The Journal of Dermatology.2023; 50(9): 1108.     CrossRef
  • Real‐world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors
    Srilatha Dasari, William Tse, Jiasheng Wang
    British Journal of Haematology.2023; 202(6): 1205.     CrossRef
  • Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors
    André Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, Stellio Giacomini, Sébastien Bugeia, Garance Gutknecht, Gilliosa Spurrier-Bernard, Veronica Aedo-Lopez, Nuria Mederos, Sofiya Latifyan, Alfredo Addedo, Olivier Michielin, Manuela Eicher
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • CD4 T cells and toxicity from immune checkpoint blockade
    Noah Earland, Wubing Zhang, Abul Usmani, Aishwarya Nene, Antonella Bacchiocchi, David Y. Chen, Mario Sznol, Ruth Halaban, Aadel A. Chaudhuri, Aaron M. Newman
    Immunological Reviews.2023; 318(1): 96.     CrossRef
  • Anti‑PD1 therapy‑associated distal renal tubular acidosis: A case report
    Xuejia Qiu, Bingnan Ren, Lingzhi Fang, Zhanjun Dong
    Experimental and Therapeutic Medicine.2023;[Epub]     CrossRef
  • Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review
    Minoru Kato, Junji Uchida
    International Journal of Urology.2023; 30(12): 1068.     CrossRef
  • Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab
    Manuel A. Baarslag, Joosje H. Heimovaara, Jessica S.W. Borgers, Koen J. van Aerde, Hans J.P.M. Koenen, Ruben L. Smeets, Pauline L.M. Buitelaar, Dick Pluim, Shoko Vos, Stefanie S.V. Henriet, Jan Willem B. de Groot, Martine van Grotel, Hilde Rosing, Jos H.
    New England Journal of Medicine.2023; 389(19): 1790.     CrossRef
  • Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibitor-Treated Patients: A Retrospective Observational Study
    Kou Masaki, Motoyasu Miyazaki, Hideki Kakimoto, Yuma Fukiage, Haruka Fukue, Akio Nakashima, Osamu Imakyure
    Journal of Clinical Medicine.2023; 12(24): 7564.     CrossRef
  • Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
    Priyatharcini Kejamurthy, K. T. Ramya Devi
    Medical Oncology.2023;[Epub]     CrossRef
  • Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From theAJRSpecial Series on Imaging of Inflammation
    Sara Sheikhbahaei, Charles V. Marcus, Mohammad S. Sadaghiani, Steven P. Rowe, Martin G. Pomper, Lilja B. Solnes
    American Journal of Roentgenology.2022; 218(6): 940.     CrossRef
  • Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation
    Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg, Mark J. Ratain
    The Journal of Clinical Pharmacology.2022; 62(4): 532.     CrossRef
  • T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
    Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloé B. Steen, Bogdan A. Luca, Ti Badri, Gunsagar S. Gulati, Milad R. Vahid, Farnaz Khameneh, Peter K. Harri
    Nature Medicine.2022; 28(2): 353.     CrossRef
  • Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity
    Ka Man Cheung, Therese Yue Man Tsui, James Chung Hang Chow
    Cancer.2022; 128(13): 2549.     CrossRef
  • CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
    Kenichi Nishimura, Tatsuya Konishi, Toshiki Ochi, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Katsuto Takenaka, Takashi Saika
    Journal of Personalized Medicine.2022; 12(6): 888.     CrossRef
  • A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer
    Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi
    Cancer Research and Treatment.2022; 54(4): 1005.     CrossRef
  • Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
    Ana Cardeña-Gutiérrez, Mónica López Barahona
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy
    Afaf Abed, Ngie Law, Leslie Calapre, Johnny Lo, Vikas Bhat, Samantha Bowyer, Michael Millward, Elin S. Gray
    European Journal of Cancer.2022; 172: 98.     CrossRef
  • Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma
    Dirk Tomsitz, Max Schlaak, Sarah Zierold, Giulia Pesch, Thomas U. Schulz, Genoveva Müller, Christine Zecha, Lars E. French, Lucie Heinzerling
    Cancers.2022; 14(13): 3282.     CrossRef
  • Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
    Ben-Max de Ruiter, Jons W. van Hattum, Djoeri Lipman, Theo M. de Reijke, R. Jeroen A. van Moorselaar, Erik J. van Gennep, A.H. Maartje Piet, Mila Donker, Tom van der Hulle, Jens Voortman, Jorg R. Oddens, Maarten C.C.M. Hulshof, Adriaan D. Bins
    European Urology.2022; 82(5): 518.     CrossRef
  • Adverse Renal Effects of Anticancer Immunotherapy: A Review
    Maciej Borówka, Stanisław Łącki-Zynzeling, Michał Nicze, Sylwia Kozak, Jerzy Chudek
    Cancers.2022; 14(17): 4086.     CrossRef
  • Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence
    Nari Kim, Eun Sung Lee, Sang Eun Won, Mihyun Yang, Amy Junghyun Lee, Youngbin Shin, Yousun Ko, Junhee Pyo, Hyo Jung Park, Kyung Won Kim
    Korean Journal of Radiology.2022; 23(11): 1089.     CrossRef
  • Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data
    Jiasheng Wang, Srilatha Dasari, Dina Elantably, Akram Alkrekshi, Yeseong David Kim
    Acta Oncologica.2022; 61(9): 1157.     CrossRef
  • Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
    Chan Kim, Hannah Yang, Ilhwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon
    JAMA Oncology.2022; 8(12): 1825.     CrossRef
  • Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
    Ik Shin Chin, Aman Khan, Anna Olsson-Brown, Sophie Papa, Gary Middleton, Claire Palles
    npj Genomic Medicine.2022;[Epub]     CrossRef
  • Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer
    Lance L. Munn, Triantafyllos Stylianopoulos, Natalie K. Jain, C. Corey Hardin, Melin J. Khandekar, Rakesh K. Jain
    Clinical Cancer Research.2021; 27(10): 2706.     CrossRef
  • Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
    Jonathan T. Hunt, Laura M. Chambers, Meng Yao, Amy Joehlin-Price, Robert Debernardo, Peter G. Rose
    Gynecologic Oncology Reports.2021; 37: 100840.     CrossRef
  • Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy
    Jie Zhang, Zhujiang Dai, Cheng Yan, Daorong Wang, Dong Tang
    Journal of Cancer Research and Clinical Oncology.2021; 147(12): 3639.     CrossRef
  • Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
    Jay M. Lee, Anthony W. Kim, Tomasz Marjanski, Pierre-Emmanuel Falcoz, Masahiro Tsuboi, Yi-Long Wu, Shawn W. Sun, Barbara J. Gitlitz
    JTO Clinical and Research Reports.2021; 2(10): 100221.     CrossRef
  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
    Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Monalisa Ghosh, Ishmael
    Journal of Clinical Oncology.2021; 39(36): 4073.     CrossRef
  • Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
    Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Ke Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan, Liang Han, Shenghao Tu
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • 24,720 View
  • 882 Download
  • 163 Web of Science
  • 168 Crossref
Close layer
Patterns of Failure and Survival Trends in 3,808 Patients with Stage II Nasopharyngeal Carcinoma Diagnosed from 1990 to 2012: A Large-Scale Retrospective Cohort Study
Xue-Song Sun, Di-Han Liu, Sai-Lan Liu, Qiu-Yan Chen, Shan-Shan Guo, Yue-Feng Wen, Li-Ting Liu, Hao-Jun Xie, Qing-Nan Tang, Yu-Jing Liang, Xiao-Yun Li, Jin-Jie Yan, Ming-Huang Hong, Jun Ma, Lin-Quan Tang, Hai-Qiang Mai
Cancer Res Treat. 2019;51(4):1449-1463.   Published online March 7, 2019
DOI: https://doi.org/10.4143/crt.2018.688
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate the survival trends and patterns of failure in patients with stage II nasopharyngeal carcinoma (NPC) treated with radiotherapy (RT) and chemotherapy over the last 20 years.
Materials and Methods
Thirty-eight hundred and eight patients diagnosed with stage II NPC between January 1990 and December 2012 were involved in this retrospective cohort study. All patients were treated with RT. According to the main imaging techniques and RT technology, we categorized these patients into four calendar periods: 1990-1996, 1997-2002, 2003-2007, and 2008-2012. Overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRFS), and distant metastasis–free survival (DMFS) were served as the clinical outcome.
Results
After a median follow-up period of 84.7 months, we observed increasing trends in survival and disease control. The 3- and 5-year OS rates increased from 87.1% and 78.7% in the first calendar period to 97.4% and 94.5% in the last calendar period, respectively (p<0.001). Additionally, significant increasing trends could be seen in the PFS and LRFS during the four calendar periods. In the subgroup analysis, the LRFS in patients older than 50 years at diagnosis showed greater improvement than younger patients. However, the rate of distant metastasis was stable and relatively low, as the 5-year DMFS ranged from 90.5% to 94.7% among the four calendar periods.
Conclusion
The survival rates in patients with stage II NPC showed increasing trends from 1990 to 2012. The advance of RT provided excellent locoregional control and enhanced OS.

Citations

Citations to this article as recorded by  
  • Predicting disease progression from the rate of bodyweight change in nasopharyngeal carcinoma patient during radiotherapy
    Jiachen Sun, Sai kit Edmond Lam, Xinzhi Teng, Jiang Zhang, Francis Kar-ho Lee, Celia Wai-yi Yip, James Chung-hang Chow, Victor Ho-fun Lee, Ying Sun, Jing Cai
    Scientific Reports.2025;[Epub]     CrossRef
  • ADAM22 acts as a novel predictive biomarker for unfavorable prognosis and facilitates metastasis via PI3K/AKT signaling pathway in nasopharyngeal carcinoma
    Kaixiong Xu, Ping Jiang, Zui Chen, Xiaoqiong Gu, Ting Zhang
    Pathology - Research and Practice.2024; 256: 155264.     CrossRef
  • T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study
    Pei-Jing Li, Ming Chen, Ye Tian, Seok Ho Lee
    PLOS ONE.2023; 18(3): e0279252.     CrossRef
  • Survival among subgroups of patients with stage II nasopharyngeal carcinoma
    Shi-Ting Huang, Dan-Ke Su
    Scientific Reports.2022;[Epub]     CrossRef
  • Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta, Indonesia: A hospital-based retrospective study
    Susanna Hilda Hutajulu, Daniel Howdon, Kartika Widayati Taroeno-Hariadi, Mardiah Suci Hardianti, Ibnu Purwanto, Sagung Rai Indrasari, Camelia Herdini, Bambang Hariwiyanto, Ahmad Ghozali, Henry Kusumo, Wigati Dhamiyati, Sri Retna Dwidanarti, I. Bing Tan, J
    PLOS ONE.2021; 16(2): e0246638.     CrossRef
  • Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study
    Pei-Jing Li, Yu-Lin Lai, Fang He, Yuan-Yuan Chen, Zhuo-Sheng Gu, Wei Luo, Qun Zhang
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Systemic chemotherapy and sequential locoregional radiotherapy in initially metastatic nasopharyngeal carcinoma: Retrospective analysis with 821 cases
    Tianying Huang, Ning Su, Xuanye Zhang, Shuyun Ma, Guangzheng Zhong, Xiaopeng Tian, Qiuyan Chen, Linglong Tang, Lixia Lu, Yu Fang, Jun Cai, Qingqing Cai
    Head & Neck.2020; 42(8): 1970.     CrossRef

  • CD47 Overexpression Is Associated with Epstein–Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma


    Zhi-Hui Wang, Xiao-Feng Pei, Zhi-Quan Zhu, Zhong Lin, Yin-Yan Mao, Xiao-Lu Xu, You-Li Luo, Li Zhang, Pei-Jian Peng
    OncoTargets and Therapy.2020; Volume 13: 3325.     CrossRef
  • Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA
    Min Kang, Bo Tang, Jixi Li, Ziyan Zhou, Kang Liu, Rensheng Wang, Ziyan Jiang, Fangfang Bi, David Patrick, Dongin Kim, Anirban K. Mitra, Yang Yang-Hartwich
    Molecular Cancer.2020;[Epub]     CrossRef
  • 10,024 View
  • 156 Download
  • 11 Web of Science
  • 9 Crossref
Close layer
Cancer-Associated Fibroblasts Promote the Chemo-resistance in Gastric Cancer through Secreting IL-11 Targeting JAK/STAT3/Bcl2 Pathway
Jun Ma, Xiao Song, Xiaowu Xu, Yiping Mou
Cancer Res Treat. 2019;51(1):194-210.   Published online April 20, 2018
DOI: https://doi.org/10.4143/crt.2018.031
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Our aim was to detect the potential role of interleukin 11 (IL-11) in the development of chemo-resistance in gastric cancer and to reveal the mechanism involved in the process.
Materials and Methods
Here, we used flow cytometry to examine the percentage of cancer-associated-fibroblasts in tumor samples from chemo-resistant and -sensitive gastric cancer patients. Using MTT assay, we detected the cell viability under different conditions. Using quantitative real-time polymerase chain reaction and Western blotting, we determined the target expressions in mRNA and protein levels. We also performed immunohistochemistry and immunofluorescence to detect the target proteins under different conditions. Animal models were constructed to verify the potential role of IL-11 in chemo-resistant develop in vivo.
Results
Herein, we observed enriched cancer associated fibroblasts in drug resistant tumor tissues from gastric patients. Those fibroblasts facilitate the chemotherapeutic drugs resistance development through the secretion of IL-11, which activates the IL-11/IL-11R/gp130/ JAK/STAT3 anti-apoptosis signaling pathway in gastric cancer cells. We found that the combination of chemotherapeutic drugs and JAK inhibitor overcomes the resistance and increases the survival of mice with gastric cancer xenografts.
Conclusion
Ourresults demonstrated that IL-11 contributed to the obtain ofresistance to chemotherapy drugs through gp130/JAK/STAT3/Bcl2 pathway, and targeting the IL-11 signaling pathway induced by fibroblasts might be a promising strategy to overcome the multi-drugs resistant cancer in clinic.

Citations

Citations to this article as recorded by  
  • The role of cytokines in ovarian cancer drug resistance
    Lu Wang, Yunxia Zang, Rebeka Dejenie, Junyuan Bing, Shixia Dong, Yanfei Zhang, Yi Zhu, Jingjing Li
    International Journal of Cancer.2026; 158(4): 821.     CrossRef
  • Cancer-associated fibroblast-derived GAS6 increases resistance to chemotherapy through AXL/STAT3/ABCG1 in gastric cancer
    Tae Hoon Kim, Dagyeong Lee, Hye Jeong Oh, In-Hye Ham, Tuyen Thanh Tran, Yulim Lee, Tae-Min Kim, Rolf A. Brekken, Zhang Zhang, Ding Ke, Hoon Hur
    British Journal of Cancer.2026; 134(1): 72.     CrossRef
  • IL-11–IL6ST–STAT3 signaling defines a convergent inflammatory axis in esophageal cancer subtypes
    Shayaq Ul Abeer Rasool, Arshad A. Pandith, Farooq Ahmad Ganie, Qurat ul Aein, Usma Manzoor, Dil Afroze, Aadil Manzoor Baba, Zubaida Rasool, Nazir Ahmad Dar, Showkeen Muzamil
    Scientific Reports.2026;[Epub]     CrossRef
  • Anticancer evaluation of ferrocene-modified half-sandwich ruthenium(II) acylhydrazone complexes against A549 cell lines
    Yuan Gao, Xiaoshuang Li, Jia Wen, Yuxin Zhang, Yongfeng Liu, Luoyi Bu, Shuying Cao, Xicheng Liu, Xiang-ai Yuan, Zhe Liu
    Journal of Inorganic Biochemistry.2026; 282: 113347.     CrossRef
  • CAF enhances pancreatic cancer EMT and chemo-resistance
    ShaoBo ZHANG, Qiong ZENG, MingYang LIU
    SCIENTIA SINICA Vitae.2026;[Epub]     CrossRef
  • Role of Soluble Cytokine Receptors in Gastric Cancer Development and Chemoresistance
    Francesca Lospinoso Severini, Geppino Falco, Tiziana Notarangelo
    International Journal of Molecular Sciences.2025; 26(6): 2534.     CrossRef
  • The role of the tumor microenvironment and inflammatory pathways in driving drug resistance in gastric cancer: A systematic review and meta-analysis
    Francesco Albano, Francesca Lospinoso Severini, Giovanni Calice, Pietro Zoppoli, Geppino Falco, Tiziana Notarangelo
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(6): 167821.     CrossRef
  • The extracellular matrix in cancer: from understanding to targeting
    Jessica L. Chitty, Thomas R. Cox
    Trends in Cancer.2025; 11(9): 839.     CrossRef
  • AI-Powered Insights into Drug Resistance in Gastric Cancer: A Path Toward Precision Therapy
    Negar Mottaghi-Dastjerdi, Mohammad Soltany-Rezaee-Rad
    Iranian Journal of Pharmaceutical Research.2025;[Epub]     CrossRef
  • Precancerous pathways to gastric cancer: a review of experimental animal models recapitulating the correa cascade
    Weiqing Li, Tai Zhang
    Frontiers in Cell and Developmental Biology.2025;[Epub]     CrossRef
  • The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors
    Xinhao Zhang, Yuhang Wang, Wenming Cui, Danyang Li, Junmin Song, Zhen Li, Ying Liu, Shuaixi Yang
    Drug Resistance Updates.2025; 82: 101273.     CrossRef
  • STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer
    Xuchen Fan, Sheng Wu, Honglong Wu, Yingying Huang, Xuhui Tong, Meiling Yu, Zhe Liu
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • POSTN is exclusively activated in cancer‑associated fibroblasts and leads to unfavorable prognosis of patients with gastric cancer
    Ching To, Fuda Xie, Peiyao Yu, Jialin Wu, Yang Lyu, Bonan Chen, Tiejun Feng, Hoi Leung, Wei Kang
    Molecular and Clinical Oncology.2025; 23(3): 1.     CrossRef
  • Fibroblast activation protein: Pivoting cancer/chemotherapeutic insight towards heart failure
    John Gehris, Charlie Ervin, Charlotte Hawkins, Sydney Womack, Amelia M. Churillo, Jonathan Doyle, Albert J. Sinusas, Francis G. Spinale
    Biochemical Pharmacology.2024; 219: 115914.     CrossRef
  • Interleukin-6 Family of Cytokines in Cancers
    Iwona Zaporowska-Stachowiak, Michał Springer, Katarzyna Stachowiak, Mary Oduah, Maciej Sopata, Katarzyna Wieczorowska-Tobis, Wiesław Bryl
    Journal of Interferon & Cytokine Research.2024; 44(2): 45.     CrossRef
  • Exosome as a crucial communicator between tumor microenvironment and gastric cancer (Review)
    Menghui Wang, Hongxin Shu, Xifu Cheng, Hong Xiao, Zhenhua Jin, Nan Yao, Shengxun Mao, Zhen Zong
    International Journal of Oncology.2024;[Epub]     CrossRef
  • Tumor cell stemness in gastrointestinal cancer: regulation and targeted therapy
    Kangqi Yang, Tuo Yi
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Cancer-associated fibroblasts: protagonists of the tumor microenvironment in gastric cancer
    Ece Ozmen, Tevriz Dilan Demir, Gulnihal Ozcan
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer
    Peiyuan Li, Huan Zhang, Tao Chen, Yajing Zhou, Jiaoyang Yang, Jin Zhou
    Matrix Biology.2024; 132: 59.     CrossRef
  • Anlotinib inhibits cervical cancer cell proliferation and invasion by suppressing cytokine secretion in activated cancer-associated fibroblasts
    Yaozu Xiong, Xiaoting Xu, Xilei Zhou, Yusuo Tong, Changhua Yu
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution
    Fusheng Zhang, Yongsu Ma, Dongqi Li, Jianlei Wei, Kai Chen, Enkui Zhang, Guangnian Liu, Xiangyu Chu, Xinxin Liu, Weikang Liu, Xiaodong Tian, Yinmo Yang
    Journal of Hematology & Oncology.2024;[Epub]     CrossRef
  • Induction, growth, drug resistance, and metastasis: A comprehensive summary of the relationship between STAT3 and gastric cancer
    Muyang Chen, Tongshan Wang, Dianzhe Tian, Chaorui Hai, Zixuan Qiu
    Heliyon.2024; 10(18): e37263.     CrossRef
  • Drug resistance and tumor immune microenvironment: An overview of current understandings (Review)
    Yan Liu, Jun Liang, Yanping Zhang, Qie Guo
    International Journal of Oncology.2024;[Epub]     CrossRef
  • Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?
    Shadiya Fawzul Ameer, Muna Yusuf Mohamed, Qubaa Ahmed Elzubair, Elham Abdullatif M. Sharif, Wisam Nabeel Ibrahim
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer
    Zhiyang Zhou, Sixuan Guo, Shuhui Lai, Tao Wang, Yao Du, Junping Deng, Shun Zhang, Ge Gao, Jiangnan Zhang
    BMC Cancer.2023;[Epub]     CrossRef
  • Cold atmospheric plasma: Novel opportunities for tumor microenvironment targeting
    Xiaofeng Dai, Kaiyuan Zhu
    Cancer Medicine.2023; 12(6): 7189.     CrossRef
  • Podoplanin promotes the carcinogenicity of gastric cancer by activating ezrin and mediating the crosstalk between tumour cells and cancer‐associated fibroblasts
    Yueli Tian, Xin Chen, Xiaodong Wang, Ying Song
    Experimental Physiology.2023; 108(5): 740.     CrossRef
  • Cancer-associated fibroblast-derived exosome microRNA-21 promotes angiogenesis in multiple myeloma
    Sun Miaomiao, Wang Xiaoqian, Shou Yuwei, Chen Chao, Yang Chenbo, Liang Yinghao, Hong Yichen, Shu Jiao, Chen Kuisheng
    Scientific Reports.2023;[Epub]     CrossRef
  • An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma
    Brianna J. McIntosh, Griffin G. Hartmann, Sean A. Yamada‐Hunter, Phillip Liu, Camille F. Williams, Julien Sage, Jennifer R. Cochran
    Bioengineering & Translational Medicine.2023;[Epub]     CrossRef
  • Targeting carcinoma‐associated mesothelial cells with antibody–drug conjugates in ovarian carcinomatosis
    Lucía Pascual‐Antón, Pilar Sandoval, Guadalupe T González‐Mateo, Valeria Kopytina, Henar Tomero‐Sanz, Eva María Arriero‐País, José Antonio Jiménez‐Heffernan, Myriam Fabre, Isabel Egaña, Cristina Ferrer, Laureano Simón, Lucía González‐Cortijo, Ricardo Sain
    The Journal of Pathology.2023; 261(2): 238.     CrossRef
  • Chemoresistant fibroblasts dictate neoadjuvant chemotherapeutic response of head and neck cancer via TGFα-EGFR paracrine signaling
    Liangping Su, Sangqing Wu, Cheng Huang, Xianhua Zhuo, Jiali Chen, Xue Jiang, Xiangzhan Kong, Cui Lv, Qiuping Xu, Ping Han, Xiaoming Huang, Ping-Pui Wong
    npj Precision Oncology.2023;[Epub]     CrossRef
  • A bibliometric and visual analysis of cancer-associated fibroblasts
    Wei-Chen Yuan, Jie-Xiang Zhang, Hai-Bin Chen, Ying Yuan, Yu-Pei Zhuang, Hong-Li Zhou, Mu-Han Li, Wen-Li Qiu, Hong-Guang Zhou
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword
    Mohammad Heydarian, Mohammadjavad Mohammadtaghizadeh, Mahboobeh Shojaei, Marziyeh Babazadeh, Sadegh Abbasian, Mehran Amrovani
    Molecular Biology Reports.2022; 49(1): 605.     CrossRef
  • Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance
    Pradip De, Jennifer Aske, Raed Sulaiman, Nandini Dey
    Cancers.2022; 14(6): 1519.     CrossRef
  • Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone
    Ruo-Yi Huang, Hao-Wei Kou, Puo-Hsien Le, Chia-Jung Kuo, Tsung-Hsing Chen, Shang-Yu Wang, Jen-Shi Chen, Ta-Sen Yeh, Jun-Te Hsu
    Journal of Personalized Medicine.2022; 12(4): 555.     CrossRef
  • Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures
    Bing Feng, Jianzhong Wu, Bo Shen, Feng Jiang, Jifeng Feng
    Cancer Cell International.2022;[Epub]     CrossRef
  • Curcumin inhibits the cancer‑associated fibroblast‑derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway
    In-Hye Ham, Lei Wang, Dagyeong Lee, Jongsu Woo, Tae Kim, Hye Jeong, Hye Oh, Kyeong Choi, Tae-Min Kim, Hoon Hur
    International Journal of Oncology.2022;[Epub]     CrossRef
  • Role of Interleukins and New Perspectives in Mechanisms of Resistance to Chemotherapy in Gastric Cancer
    Marlena Janiczek-Polewska, Łukasz Szylberg, Julian Malicki, Andrzej Marszałek
    Biomedicines.2022; 10(7): 1600.     CrossRef
  • Interleukin-11: A Potential Biomarker and Molecular Therapeutic Target in Non-Small Cell Lung Cancer
    Jason Hongting Leung, Benjamin Ng, Wei-Wen Lim
    Cells.2022; 11(14): 2257.     CrossRef
  • Over-expression of NFYB affects stromal cells reprogramming and predicts worse survival in gastric cancer patients
    Tailiang Lu, Chenglong Li, Cailing Xiang, Yongqiang Gong, Wei Peng, Futao Hou, Chaowu Chen
    Aging.2022; 14(19): 7851.     CrossRef
  • Drug Resistance in Cancers: A Free Pass for Bullying
    Jing Li, Xiao Li, Qie Guo
    Cells.2022; 11(21): 3383.     CrossRef
  • Exosomal long non-coding RNAs: novel molecules in gastrointestinal cancers’ progression and diagnosis
    Mohammad Roshani, Ghazaleh Baniebrahimi, Mahboubeh Mousavi, Noushid Zare, Reza Sadeghi, Reza Salarinia, Amirhossein Sheida, Danial Molavizadeh, Sara Sadeghi, Farzaneh Moammer, Mohammad Reza Zolfaghari, Hamed Mirzaei
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • CAFs-Derived Exosomal miRNA-130a Confers Cisplatin Resistance of NSCLC Cells Through PUM2-Dependent Packaging
    Tao Zhang, Ping Zhang, Hong-Xia Li
    International Journal of Nanomedicine.2021; Volume 16: 561.     CrossRef
  • PKM2 promotes cell metastasis and inhibits autophagy via the JAK/STAT3 pathway in hepatocellular carcinoma
    Zhi Yu, Dan Wang, Yingying Tang
    Molecular and Cellular Biochemistry.2021; 476(5): 2001.     CrossRef
  • Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis
    Peng Deng, Ming Sun, Wen-Yan Zhao, Bin Hou, Kai Li, Tao Zhang, Feng Gu
    World Journal of Gastroenterology.2021; 27(6): 487.     CrossRef
  • Cancer-Associated Fibroblast-Induced Resistance to Chemotherapy and Radiotherapy in Gastrointestinal Cancers
    In-Hye Ham, Dagyeong Lee, Hoon Hur
    Cancers.2021; 13(5): 1172.     CrossRef
  • Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy
    Takahiro Ishii, Ayako Suzuki, Takeshi Kuwata, Shoshi Hisamitsu, Hiroko Hashimoto, Yuuki Ohara, Kazuyoshi Yanagihara, Shuichi Mitsunaga, Takayuki Yoshino, Takahiro Kinoshita, Atsushi Ochiai, Kohei Shitara, Genichiro Ishii
    Gastric Cancer.2021; 24(4): 810.     CrossRef
  • Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential
    Adriana Carino, Luigina Graziosi, Silvia Marchianò, Michele Biagioli, Elisabetta Marino, Valentina Sepe, Angela Zampella, Eleonora Distrutti, Annibale Donini, Stefano Fiorucci
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Inflammation-Induced Tumorigenesis and Metastasis
    Sana Hibino, Tetsuro Kawazoe, Hidenori Kasahara, Shinji Itoh, Takatsugu Ishimoto, Mamiko Sakata-Yanagimoto, Koji Taniguchi
    International Journal of Molecular Sciences.2021; 22(11): 5421.     CrossRef
  • The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
    Yanghong Ni, Xiaoting Zhou, Jia Yang, Houhui Shi, Hongyi Li, Xia Zhao, Xuelei Ma
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
    Fanglong Wu, Jin Yang, Junjiang Liu, Ye Wang, Jingtian Mu, Qingxiang Zeng, Shuzhi Deng, Hongmei Zhou
    Signal Transduction and Targeted Therapy.2021;[Epub]     CrossRef
  • Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy
    Pradip De, Jennifer Aske, Nandini Dey
    Cancers.2021; 13(20): 5246.     CrossRef
  • Induction of interleukin-11 mediated by RhoA GTPase during human cytomegalovirus lytic infection
    Saud Alarifi, Saad Alkahtani, Ahmed A. Al-Qahtani, Christos Stournaras, George Sourvinos
    Cellular Signalling.2020; 70: 109599.     CrossRef
  • Tumor-Secreted Exosomal lncRNA POU3F3 Promotes Cisplatin Resistance in ESCC by Inducing Fibroblast Differentiation into CAFs
    Yusuo Tong, Lili Yang, Changhua Yu, Weiguo Zhu, Xilei Zhou, Yaozu Xiong, Wanwei Wang, Fuzhi Ji, Dongcheng He, Xiufeng Cao
    Molecular Therapy - Oncolytics.2020; 18: 1.     CrossRef
  • STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
    Milad Ashrafizadeh, Ali Zarrabi, Sima Orouei, Vahideh Zarrin, Ebrahim Rahmani Moghadam, Amirhossein Zabolian, Shima Mohammadi, Kiavash Hushmandi, Yashar Gharehaghajlou, Pooyan Makvandi, Masoud Najafi, Reza Mohammadinejad
    Biology.2020; 9(6): 126.     CrossRef
  • Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma
    Jose J. G. Marin, Laura Perez-Silva, Rocio I. R. Macias, Maitane Asensio, Ana Peleteiro-Vigil, Anabel Sanchez-Martin, Candela Cives-Losada, Paula Sanchon-Sanchez, Beatriz Sanchez De Blas, Elisa Herraez, Oscar Briz, Elisa Lozano
    Cancers.2020; 12(8): 2116.     CrossRef
  • Glycochenodeoxycholic acid induces stemness and chemoresistance via the STAT3 signaling pathway in hepatocellular carcinoma cells
    Changying Shi, Jiamei Yang, Longmiao Hu, Boyi Liao, Liang Qiao, Weifeng Shen, Feng Xie, Guoqing Zhu
    Aging.2020; 12(15): 15546.     CrossRef
  • Cancer-associated fibroblasts-derived gamma-glutamyltransferase 5 promotes tumor growth and drug resistance in lung adenocarcinoma
    Jia-Ru Wei, Jun Dong, Lei Li
    Aging.2020; 12(13): 13220.     CrossRef
  • Emerging roles for the IL-6 family of cytokines in pancreatic cancer
    Gemma van Duijneveldt, Michael D.W. Griffin, Tracy L. Putoczki
    Clinical Science.2020; 134(16): 2091.     CrossRef
  • Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments
    In-Hye Ham, Dagyeong Lee, Hoon Hur
    Journal of Oncology.2019; 2019: 1.     CrossRef
  • The long non‐coding RNA OLC8 enhances gastric cancer by interaction with IL‐11
    Rongjia Zhou, Zhanbin Wu, Xixiang Deng, Haojun Chen
    Journal of Clinical Laboratory Analysis.2019;[Epub]     CrossRef
  • Adapting and Surviving: Intra and Extra-Cellular Remodeling in Drug-Resistant Gastric Cancer Cells
    Sabino Russi, Henu Kumar Verma, Simona Laurino, Pellegrino Mazzone, Giovanni Storto, Anna Nardelli, Pietro Zoppoli, Giovanni Calice, Francesco La Rocca, Alessandro Sgambato, Valeria Lucci, Geppino Falco, Vitalba Ruggieri
    International Journal of Molecular Sciences.2019; 20(15): 3736.     CrossRef
  • The pro-tumorigenic host response to cancer therapies
    Yuval Shaked
    Nature Reviews Cancer.2019; 19(12): 667.     CrossRef
  • Dracorhodin perchlorate induces apoptosis and G2/M cell cycle arrest in human esophageal squamous cell carcinoma through inhibition of the JAK2/STAT3 and AKT/FOXO3a pathways
    Zhengyang Lu, Chenyang Lu, Cheng Li, Yan Jiao, Yanqing Li, Guangxin Zhang
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Near-infrared fluorescent labeled CGRRAGGSC peptides for optical imaging of IL-11Rα in athymic mice bearing tumor xenografts
    Tiannv Li, Jin Sun, Yao Hu, Min Yang, Haibin Shi, Lijun Tang
    The Journal of Biomedical Research.2019; 33(6): 391.     CrossRef
  • 18,335 View
  • 485 Download
  • 73 Web of Science
  • 65 Crossref
Close layer
Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis
Yang Li, Lin-Quan Tang, Li-Ting Liu, Shan-Shan Guo, Yu-Jing Liang, Xue-Song Sun, Qing-Nan Tang, Jin-Xin Bei, Jing Tan, Shuai Chen, Jun Ma, Chong Zhao, Qiu-Yan Chen, Hai-Qiang Mai
Cancer Res Treat. 2018;50(4):1304-1315.   Published online January 8, 2018
DOI: https://doi.org/10.4143/crt.2017.463
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the long-term clinical outcome and toxicity of induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) compared with CCRT alone for the treatment of children and adolescent locoregionally advanced nasopharyngeal carcinoma (LACANPC).
Materials and Methods
A total of 194 locoregionally advanced nasopharyngeal carcinoma patients youngerthan 21 years who received CCRT with or without IC before were included in the study population. Overall survival (OS) rate, progression-free survival (PFS) rate, locoregional recurrence-free survival (LRFS) rate, and distant metastasis-free survival (DMFS) rate were assessed by the Kaplan-Meier method and a log-rank test. Treatment toxicities were clarified and compared between two groups.
Results
One hundred and thiry of 194 patients received IC+CCRT. Patients who were younger and with more advanced TNM stage were more likely to receive IC+CCRT and intensive modulated radiotherapy. The addition of IC before CCRT failed to improve survival significantly. The matched analysis identified 43 well-balanced patients in both two groups. With a median follow-up of 51.5 months, no differences were found between the IC+CCRT group and the CCRT group in 5-year OS (83.7% vs. 74.6%, p=0.153), PFS (79.2% vs. 73.4%, p=0.355), LRFS (97.7% vs. 88.2%, p=0.083), and DMFS (81.6% vs. 81.6%, p=0.860). N3 was an independent prognostic factor predicting poorer OS, PFS, and DMFS. The addition of IC was associated with increased rates of grade 3 to 4 neutropenia.
Conclusion
This study failed to demonstrate that adding IC before CCRT could provide a significant additional survival benefit for LACANPC patients. Further investigations are warranted.

Citations

Citations to this article as recorded by  
  • Nasopharyngeal Carcinoma in Children, Current Treatment Approach
    Tal Ben-Ami
    Journal of Pediatric Hematology/Oncology.2024; 46(3): 117.     CrossRef
  • Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study
    Ya-Nan Jin, Zhao-Hui Ruan, Wan-Wei Cao, Lin Yang, Wei Yao, Xiao-Feng Pei, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
    Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11929.     CrossRef
  • Epidemiology and treatment of head and neck malignancies in the AYA generation
    Takahiro Asakage
    International Journal of Clinical Oncology.2022; 27(3): 465.     CrossRef
  • Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020
    Yu-Jing Liang, Li-Ting Liu, Yang Li, Pan Wang, Mei-Juan Luo, Dong-Xiang Wen, Qiu-Yan Chen, Hai-Qiang Mai
    JAMA Network Open.2022; 5(3): e220173.     CrossRef
  • LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis
    Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan
    British Journal of Cancer.2022; 127(7): 1239.     CrossRef
  • Exploring the Optimal Chemotherapy Strategy for Locoregionally Advanced Children and Adolescent Nasopharyngeal Carcinoma Based on Pretreatment Epstein-Barr Virus DNA Level in the Era of Intensity Modulated Radiotherapy
    Ziyi Zeng, Chen Chen, Lanlan Guo, Cheng Zhang, Lei Chen, Chuanping Yuan, Lixia Lu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study
    Ya-Nan Jin, Ji-Jin Yao, Ya-Fei You, Hui-Jiao Cao, Zi-Zi Li, Dan-Ling Dai, Wang-Jian Zhang, Tia Marks, Bei Zhang, Liang-Ping Xia
    Radiotherapy and Oncology.2021; 161: 83.     CrossRef
  • Nasopharyngeal carcinoma in children: Multimodal treatment and long‐term outcome of 92 patients in a single center over a 28‐year period
    Rejin Kebudi, Sema Bay Buyukkapu, Omer Gorgun, Kübra Ozkaya, Rasim Meral, Inci Ayan, Musa Altun
    Pediatric Blood & Cancer.2021;[Epub]     CrossRef
  • Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA
    Yu-Jing Liang, Dong-Xiang Wen, Mei-Juan Luo, Lin-Quan Tang, Shan-Shan Guo, Pan Wang, Qiu-Yan Chen, Li-Ting Liu, Hai-Qiang Mai
    European Journal of Cancer.2021; 159: 133.     CrossRef
  • Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma
    Demin Liu, Haojiang Li, Liyang Wu, Shuchao Chen, Tianqiao Zhang, Wenjie Huang, Guangying Ruan, Sai Li, Lizhi Liu, Hongbo Chen
    IEEE Access.2021; 9: 98701.     CrossRef
  • LHX2 Facilitates the Progression of Nasopharyngeal Carcinoma via Activation of the FGF1/FGFR Axis
    Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Prognostic impact of immunohistopathologic features in definitive radiation therapy for nasopharyngeal cancer patients
    Naoya Murakami, Taisuke Mori, Yuko Kubo, Seiichi Yoshimoto, Kimiteru Ito, Yoshitaka Honma, Takao Ueno, Kenya Kobayashi, Hiroyuki Okamoto, Narikazu Boku, Kana Takahashi, Koji Inaba, Kae Okuma, Hiroshi Igaki, Yuko Nakayama, Jun Itami
    Journal of Radiation Research.2020; 61(1): 161.     CrossRef
  • The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis
    Bi-Cheng Wang, Bo-Ya Xiao, Guo-He Lin, Chang Wang, Quentin Liu
    BMC Cancer.2020;[Epub]     CrossRef
  • Update in pediatric nasopharyngeal undifferentiated carcinoma
    Line Claude, Emmanuel Jouglar, Loig Duverge, Daniel Orbach
    The British Journal of Radiology.2019;[Epub]     CrossRef
  • 11,268 View
  • 214 Download
  • 19 Web of Science
  • 14 Crossref
Close layer
Proposal of a Pretreatment Nomogram for Predicting Local Recurrence after Intensity-Modulated Radiation Therapy in T4 Nasopharyngeal Carcinoma: A Retrospective Review of 415 Chinese Patients
Lu-Lu Zhang, Yi-Yang Li, Jiang Hu, Guan-Qun Zhou, Lei Chen, Wen-Fei Li, Ai-Hua Lin, Jun Ma, Zhen-Yu Qi, Ying Sun
Cancer Res Treat. 2018;50(4):1084-1095.   Published online November 15, 2017
DOI: https://doi.org/10.4143/crt.2017.359
AbstractAbstract PDFPubReaderePub
Purpose
Local relapse-free survival (LRFS) differs widely among patients with T4 category nasopharyngeal carcinoma (NPC). We aimed to build a nomogram incorporating clinicopathological information to predict LRFS in T4 NPC after definitive intensity-modulated radiation therapy (IMRT).
Materials and Methods
Retrospective study of 415 Chinese patients with non-metastatic T4 NPC treated with definitive IMRT with or without chemotherapy at our cancer center between October 2009 and September 2013. The nomogram for LRFS at 3 and 5 years was generated based on multivariate Cox proportional hazards regression, and validated using bootstrap resampling, assessing discriminative performance using the concordance index (C-index) and determining calibration ability via calibration curves.
Results
Five-year LRFS was 88.8%. We identified and incorporated four independent prognostic factors for LRFS: ethmoid sinus invasion, primary gross tumor volume, age, and pretreatment body mass index. The C-index of the nomogram for local recurrence was 0.732 (95% confidence interval, 0.726 to 0.738), indicating excellent predictive accuracy. The calibration curve revealed excellent agreement between nomogram-predicted and observed LRFS probabilities. Risk subgroups based on total point score cutoff values enabled effective discrimination of LRFS.
Conclusion
This pretreatment nomogram enables clinicians to accurately predict LRFS in T4 NPC after definitive IMRT, and could help to facilitate personalized patient counselling and treatment strategies.

Citations

Citations to this article as recorded by  
  • An 18F-FDG PET/CT-based radiomics nomogram for predicting progression-free survival in nasopharyngeal carcinoma: A retrospective cohort study
    Jianpeng Lin, Jinghua Liu, Yanli Liu, Zhendong Cao, Dong Wen, Yanjun Wu, Zhongxiao Wang, Xiaolei Zhang, Bingzhen Wang, Shuyan Li, Xianling Dong
    Medicine.2026; 105(7): e47716.     CrossRef
  • Radiomics and Deep Learning in Nasopharyngeal Carcinoma: A Review
    Zipei Wang, Mengjie Fang, Jie Zhang, Linquan Tang, Lianzhen Zhong, Hailin Li, Runnan Cao, Xun Zhao, Shengyuan Liu, Ruofan Zhang, Xuebin Xie, Haiqiang Mai, Sufang Qiu, Jie Tian, Di Dong
    IEEE Reviews in Biomedical Engineering.2024; 17: 118.     CrossRef
  • Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma
    Huan Liang, Weilin Tan, Jie Wang, Mengdan Li, Hua Pang, Xiaohui Wang, Lu Yang, Xingguo Jing
    Annals of Nuclear Medicine.2024; 38(10): 802.     CrossRef
  • Can Epstein–Barr virus‐deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
    Qun Zhang, Zhen‐Wei Peng, Zhuo‐Sheng Gu, Yan Wang, Fang He, Wen‐Bin Zhao, Wei Luo, Yong‐Yu Mei
    Cancer Medicine.2023; 12(1): 223.     CrossRef
  • Prioritizing sufficient dose to gross tumor volume over normal tissue sparing in intensity‐modulated radiotherapy treatment of T4 nasopharyngeal carcinoma
    Yanyan Chen, Quxia Zhang, Tianzhu Lu, Cairong Hu, Jingfeng Zong, Yun Xu, Wei Zheng, Lisha Chen, Senan Lin, Sufang Qiu, Luying Xu, Jianji Pan, Qiaojuan Guo, Shaojun Lin
    Head & Neck.2023; 45(5): 1130.     CrossRef
  • Multi-task deep learning-based radiomic nomogram for prognostic prediction in locoregionally advanced nasopharyngeal carcinoma
    Bingxin Gu, Mingyuan Meng, Mingzhen Xu, David Dagan Feng, Lei Bi, Jinman Kim, Shaoli Song
    European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(13): 3996.     CrossRef
  • Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma
    Shan-Shan Guo, Yan-Zhou Chen, Li-Ting Liu, Rong-Ping Liu, Yu-Jing Liang, Dong-Xiang Wen, Jing Jin, Lin-Quan Tang, Hai-Qiang Mai, Qiu-Yan Chen
    BMC Cancer.2022;[Epub]     CrossRef
  • DeepMTS: Deep Multi-Task Learning for Survival Prediction in Patients With Advanced Nasopharyngeal Carcinoma Using Pretreatment PET/CT
    Mingyuan Meng, Bingxin Gu, Lei Bi, Shaoli Song, David Dagan Feng, Jinman Kim
    IEEE Journal of Biomedical and Health Informatics.2022; 26(9): 4497.     CrossRef
  • Development and Validation of Prognostic Nomograms Based on Gross Tumor Volume and Cervical Nodal Volume for Nasopharyngeal Carcinoma Patients With Concurrent Chemoradiotherapy
    Cui-Dai Zhang, Mei Li, Ying-Ji Hong, Ze-Man Cai, Kai-Chun Huang, Zhi-Xiong Lin, Zhi-Ning Yang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area
    Ji-Jin Yao, Li Lin, Tian-Sheng Gao, Wang-Jian Zhang, Wayne R. Lawrence, Jun Ma, Ying Sun
    Cancer Research and Treatment.2021; 53(3): 657.     CrossRef
  • Nomogram predict relapse-free survival of patients with thymic epithelial tumors after surgery
    Yang-Yu Huang, Lei-Lei Wu, Xuan Liu, Shen-Hua Liang, Guo-Wei Ma
    BMC Cancer.2021;[Epub]     CrossRef
  • Establishment and validation of a nomogram with intratumoral heterogeneity derived from 18F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma
    Bingxin Gu, Jianping Zhang, Guang Ma, Shaoli Song, Liqun Shi, Yingjian Zhang, Zhongyi Yang
    BMC Cancer.2020;[Epub]     CrossRef

  • Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics


    Peiyun Long, Youya Zang, Huan Wang, Xiumei Liang, Xuekun Xie, Zhiwei Han, Dongyi Lin, Zongyu Wang, Shan Huang, Chuang Chen
    OncoTargets and Therapy.2020; Volume 13: 2093.     CrossRef
  • Impact of Paranasal Sinus Invasion on Oncologic and Dosimetric Outcomes in Nasopharyngeal Carcinoma Following Intensity-Modulated Radiation Therapy—Implications for Risk Stratification and Planning Optimization
    Xin Zhou, Xiayun He, Fen Xue, Xiaomin Ou, Chaosu Hu
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients
    Nicola Alessandro Iacovelli, Alessandro Cicchetti, Anna Cavallo, Salvatore Alfieri, Laura Locati, Eliana Ivaldi, Rossana Ingargiola, Domenico A. Romanello, Paolo Bossi, Stefano Cavalieri, Chiara Tenconi, Silvia Meroni, Giuseppina Calareso, Marco Guzzo, Ce
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma
    Lu-Lu Zhang, Fei Xu, Di Song, Meng-Yao Huang, Yong-Shi Huang, Qi-Ling Deng, Yi-Yang Li, Jian-Yong Shao
    JAMA Network Open.2020; 3(12): e2029882.     CrossRef
  • Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups
    En-Hong Zhuo, Wei-Jing Zhang, Hao-Jiang Li, Guo-Yi Zhang, Bing-Zhong Jing, Jian Zhou, Chun-Yan Cui, Ming-Yuan Chen, Ying Sun, Li-Zhi Liu, Hong-Min Cai
    European Radiology.2019; 29(10): 5590.     CrossRef
  • Impact of paranasal sinus invasion on advanced nasopharyngeal carcinoma treated with intensity‐modulated radiation therapy: the validity of advanced T stage of AJCC/UICC eighth edition staging system
    Ying Wang, Jie Zhao, Yajie Zhao, Zhen Yang, Mingjun Lei, Zhanzhan Li, Rui Wei, Dengming Chen, Yuxiang He, Liangfang Shen
    Cancer Medicine.2018; 7(7): 2826.     CrossRef
  • 11,150 View
  • 203 Download
  • 19 Web of Science
  • 18 Crossref
Close layer
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
Cheng Xu, Shi-Ping Yang, Yuan Zhang, Ling-Long Tang, Guan-Qun Zhou, Xu Liu, Yan-Ping Mao, Rui Guo, Wen-Fei Li, Lei Chen, Ai-Hua Lin, Ying Sun, Jun Ma
Cancer Res Treat. 2018;50(3):777-790.   Published online July 24, 2017
DOI: https://doi.org/10.4143/crt.2017.255
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Materials and Methods
Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. Based on nadir neutrophil afterIC-1, all patientswere categorized into three groups: no/grade 1-2/grade 3-4 neutropenia. Five-year overall survival (OS) and disease-free survival (DFS) were compared between groups and subgroups stratified by IC regimen. We also explored the occurrence of IC-1–induced myelosuppression events and the minimal value of post-treatment neutrophil-to-lymphocyte ratio (post-NLRmin). Univariate/multivariate analyses were performed to investigate the effect of IC-1–induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLRmin on OS/DFS.
Results
Grade 1-2/grade 3-4 neutropeniawere associatedwith poorer OS/DFS than no neutropenia (all p < 0.05); OS/DFS were not significantly different between patients experiencing grade 1-2 vs. 3-4 neutropenia. Neutropenia had no significant effect on OS/DFS in patients receiving docetaxel–cisplatin–5-fluorouracil (TPF). Grade 1-2 (grade 3-4) neutropenia negatively influenced OS/DFS in patients receiving cisplatin–5-fluorouracil (PF) (PF and docetaxel–cisplatin [TP]; all p < 0.05). Neutropenia, two/three myelosuppression events, and high post-NLRmin (≥ 1.33) was most frequent on days 5-10, second and third week of IC-1, respectively. After adjustment for covariates, IC-1–induced neutropenia, two/three myelosuppression events, and post-NLRmin ≥ 1.33were validated as negative predictors of OS/DFS (all p < 0.05); timing of neutropenia had no significant effect.
Conclusion
Occurrence of neutropenia, number of myelosuppression events, and high post-NLRmin during PF/TP IC-1 have prognostic value for poor survival in LANPC.

Citations

Citations to this article as recorded by  
  • Associations between inflammatory biomarkers, symptoms, treatment toxicities and quality of life in people with advanced cancer receiving systemic anti-cancer treatments: a systematic review
    Helen Andersen, Wei-Hong Liu, Patsy Yates, Morgan J. Farley, Kim E. Alexander
    Supportive Care in Cancer.2026;[Epub]     CrossRef
  • Development of a simplified population pharmacokinetic–pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment
    Yoshinori Makino, Takanori Ogawa, Reiko Makihara–Ando, Naomi Sakiyama, Masahito Yamazaki, Chizuru Naito, Hiroki Takayama, Genji Ueda, Shunsuke Kohyama, Maki Todo, Yasuhiro Kuwata, Masataka Hirasaki, Tetsuya Hamaguchi
    Cancer Chemotherapy and Pharmacology.2026;[Epub]     CrossRef
  • The approach of hematologists toward managing neutropenic fever in patients with hematological malignancies: Insights from the Iraqi experience
    Alaadin Sahham Naji, Luma Essa Hamodi, Alaa Fadhil Alwan, Ahmed Mjali
    Iraqi Journal of Hematology.2025; 14(2): 243.     CrossRef
  • Prospective clinical study of the efficacy and safety of different doses of PEG recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventing leukopenia/neutropenia caused by concurrent chemoradiotherapy for cervical cancer
    Tingting Yu, Yiwei Zhang, Jiawen Li, Zhuo Li, Rui Tong
    Holistic Integrative Oncology.2024;[Epub]     CrossRef
  • Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma
    Lu‐Lu Zhang, Xi Chen, Ying‐Ying Huang, Chi‐Xiong Liang, Meng‐Yun Qiang, Zhuo‐Chen Cai, Ze‐Jiang Zhan, Ying Deng, Jia‐Yu Zhou, Hao‐Yang Huang, Xiang Guo, Xing Lv
    Cancer Medicine.2023; 12(13): 14084.     CrossRef
  • Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition)
    Jun Wang, Baosheng Li
    Precision Radiation Oncology.2023; 7(3): 150.     CrossRef
  • Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition)
    Jun Wang, Baosheng Li
    Precision Radiation Oncology.2021; 5(1): 4.     CrossRef
  • Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma
    Yuanji Xu, Zijie Wu, Wangzhong Ye, Youping Xiao, Wei Zheng, Qinyan Chen, Penggang Bai, Zhizhong Lin, Chuanben Chen
    BMC Cancer.2021;[Epub]     CrossRef
  • Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma
    Demin Liu, Haojiang Li, Liyang Wu, Shuchao Chen, Tianqiao Zhang, Wenjie Huang, Guangying Ruan, Sai Li, Lizhi Liu, Hongbo Chen
    IEEE Access.2021; 9: 98701.     CrossRef
  • Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma
    Dan Ou, Xiaoshen Wang, Mingyao Wu, Fen Xue, Yujiao Li, Chaosu Hu, Xiayun He
    Strahlentherapie und Onkologie.2020; 196(3): 252.     CrossRef
  • Amelioration of cyclophosphamide-induced myelosuppression during treatment to rats with breast cancer through low-intensity pulsed ultrasound
    Wei Wang, Dong Luo, Junlin Chen, Jinyun Chen, Yi Xia, Wenzhi Chen, Yan Wang
    Bioscience Reports.2020;[Epub]     CrossRef
  • Overview of Hematopoietic Stem Cells in Systemic Cancer Treatment, Aging, Pregnancy, and Radiation Hormesis
    Aleksei N. Shoutko
    Advances in Molecular Imaging.2019; 09(02): 19.     CrossRef
  • 15,253 View
  • 243 Download
  • 10 Web of Science
  • 12 Crossref
Close layer
A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry
Jia-Wei Lv, Xiao-Dan Huang, Yu-Pei Chen, Guan-Qun Zhou, Ling-Long Tang, Yan-Ping Mao, Wen-Fei Li, Ai-Hua Lin, Jun Ma, Ying Sun
Cancer Res Treat. 2018;50(2):324-334.   Published online April 19, 2017
DOI: https://doi.org/10.4143/crt.2016.544
AbstractAbstract PDFPubReaderePub
Purpose
Conditional survival (CS) provides important information on survival for a period of time after diagnosis. Currently, information on CS patterns of patients with nasopharyngeal carcinoma (NPC) is lacking. We aimed to analyze survival rate over time and estimate CS for NPC patients using a national population-based registry.
Materials and Methods
Patients diagnosed with NPC between 1973 and 2007 with at least 5-year follow-up were identified from the Surveillance Epidemiology End Results registry. Traditional survival rates and crude CS estimateswere calculated using Kaplan-Meier analysis. Risk-adjusted survival curves were plotted from the proportional hazards model using the correct group prognosis method.
Results
For 7,713 patients analyzed, adjusted baseline 5-year overall survival improved significantly from 36.0% in patients diagnosed in 1973-1979, 41.7% in 1980-1989, 46.6% in 1990- 1999, to 54.7% in 2000-2007 (p < 0.01). CS analysis demonstrated that for every additional year survived, adjusted probability of surviving the next 5 years increased from 66.7% (localized), 54.0% (regional), and 35.3% (distant) at the time of diagnosis, to 83.7% (localized), 75.0% (regional), and 62.2% (distant) for patients who had survived 5 years. Adjusted 5-year CS differed among age, sex, tumor histology, ethnicity, and stage subgroups initially, but converged with time.
Conclusion
Treatment outcomes of NPC patients have greatly improved over the decades. Increases in CS become more prominent in patients with distant disease than in those with localized or regional disease as patients survive longer. CS provides more dynamic prognostic information for patients who have survived a period of time after diagnosis.

Citations

Citations to this article as recorded by  
  • A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
    Anna Spreafico, Eric Winquist, Cheryl Ho, Brian O’Sullivan, Nathaniel Bouganim, Neil Chua, Sarah Doucette, Lillian L. Siu, Desiree Hao
    Current Oncology.2025; 32(1): 48.     CrossRef
  • Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities
    Suat Ming Chan, Ian C. Paterson, Lee Fah Yap
    British Journal of Biomedical Science.2025;[Epub]     CrossRef
  • Role of combined surgical and radiotherapy treatment in nonmetastatic WHO I nasopharyngeal carcinoma patients
    Zi-meng Wang, Si-yu Zhu, Qin Wang, Chong-yang Duan, Si-han Liu, Rui You, Ming-Yuan Chen, Pei-Yu Huang
    Acta Oto-Laryngologica.2024; 144(4): 325.     CrossRef
  • Health and Well-Being Needs Among Head and Neck Cancer Caregivers – A Systematic Review
    Sarah Benyo, Chandat Phan, Neerav Goyal
    Annals of Otology, Rhinology & Laryngology.2023; 132(4): 449.     CrossRef
  • Constructing an individualized surveillance framework for nasopharyngeal carcinoma based on a dynamic risk-adapted approach
    Tianzhu Lu, Hanchuan Xu, Wanfang Huang, Jingfeng Zong, Caizhu Pan, Chaobin Huang, Youping Xiao, Bijuan Chen, Jingao Li, Jianji Pan, Shaojun Lin, Fang Guo, Qiaojuan Guo
    Radiotherapy and Oncology.2023; 185: 109716.     CrossRef
  • Conditional survival nomogram for monitoring real-time survival of young non-metastatic nasopharyngeal cancer survivors
    Jianing Luo, Xiaonan Hu, Xiaofeng Ge
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10181.     CrossRef
  • Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma
    James C. H. Chow, Wah Cheuk, William C. S. Cho, Chi-Fai Wong, Dennis W. Y. Au, Anthony H. P. Tam, Rachel C. W. Wong, Jeffrey C. H. Chan, Simon C. C. Law, Roger K. C. Ngan, Kam-Hung Wong, Ka-Man Cheung
    JAMA Network Open.2023; 6(7): e2323890.     CrossRef
  • Analysis of conditional survival for primary hepatocellular carcinoma with narrow-margin hepatectomy: a large-sample, dual-center, retrospective study
    Jie Kong, Tingfeng Huang, Jianxi Zhang, Shichuan Tang, Hongzhi Liu, Jingfeng Liu, Yongyi Zeng
    HPB.2022;[Epub]     CrossRef
  • Epstein–Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments
    Oren Shechter, Daniel G. Sausen, Elisa S. Gallo, Harel Dahari, Ronen Borenstein
    International Journal of Molecular Sciences.2022; 23(22): 14389.     CrossRef
  • Health literacy impacts self-management, quality of life and fear of recurrence in head and neck cancer survivors
    Nicholas Clarke, Simon Dunne, Laura Coffey, Linda Sharp, Deirdre Desmond, Jean O’Conner, Eleanor O’Sullivan, Conrad Timon, Claire Cullen, Pamela Gallagher
    Journal of Cancer Survivorship.2021; 15(6): 855.     CrossRef
  • Development and validation of a web‐based calculator to predict individualized conditional risk of site‐specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases
    Chen‐Fei Wu, Jia‐Wei Lv, Li Lin, Yan‐Ping Mao, Bin Deng, Wei‐Hong Zheng, Dan‐Wan Wen, Yue Chen, Jia Kou, Fo‐Ping Chen, Xing‐Li Yang, Zi‐Qi Zheng, Zhi‐Xuan Li, Si‐Si Xu, Jun Ma, Ying Sun
    Cancer Communications.2021; 41(1): 37.     CrossRef
  • Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta, Indonesia: A hospital-based retrospective study
    Susanna Hilda Hutajulu, Daniel Howdon, Kartika Widayati Taroeno-Hariadi, Mardiah Suci Hardianti, Ibnu Purwanto, Sagung Rai Indrasari, Camelia Herdini, Bambang Hariwiyanto, Ahmad Ghozali, Henry Kusumo, Wigati Dhamiyati, Sri Retna Dwidanarti, I. Bing Tan, J
    PLOS ONE.2021; 16(2): e0246638.     CrossRef
  • Prognostic models for 1-year survival of NPC after radiotherapy in different ages
    Qu-xia Zhang, Lv-ping Zhuang, Zhong-yang Lin
    European Archives of Oto-Rhino-Laryngology.2021; 278(12): 4955.     CrossRef
  • Characteristics of Early Death in Patients With Localized Nasopharyngeal Cancer: A Population-Based SEER Analysis
    Haiyan Chen, Zhiheng Huang, Liubo Chen, Yanlin Li, Tiehong Zhao, Qichun Wei
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Stage‐dependent conditional survival and failure hazard of non‐metastatic nasopharyngeal carcinoma after intensity‐modulated radiation therapy: Clinical implications for treatment strategies and surveillance
    Jingbo Wang, Xiaodong Huang, Shiran Sun, Kai Wang, Yuan Qu, Xuesong Chen, Runye Wu, Ye Zhang, Qingfeng Liu, Jianghu Zhang, Jingwei Luo, Jianping Xiao, Li Gao, Guozhen Xu, Chen Hu, Ye‐Xiong Li, Junlin Yi
    Cancer Medicine.2021; 10(11): 3613.     CrossRef
  • Effects of radiotherapy in patients with nasopharyngeal carcinoma under continuous-discrete mixed mathematical model and comparison on the fungal and pathogen infection indexes before and after nutritional supplementation
    Yi Li, Xuan Li, Sahar Issa, Khairi Mohamed Omar
    Results in Physics.2021; 26: 104355.     CrossRef
  • Histological subtype remains a prognostic factor for survival in nasopharyngeal carcinoma patients
    Xing‐Xi Pan, Ya‐Jie Liu, Wen Yang, Yong‐Fa Chen, Wu‐Bing Tang, Chu‐Rong Li
    The Laryngoscope.2020;[Epub]     CrossRef
  • Association of Ambient Air Pollution with Nasopharyngeal Carcinoma Incidence in Ten Large Chinese Cities, 2006–2013
    Tianan Yang, Yexin Liu, Weigang Zhao, Zhenjiao Chen, Jianwei Deng
    International Journal of Environmental Research and Public Health.2020; 17(6): 1824.     CrossRef
  • Increasing incidence and improving survival of oral tongue squamous cell carcinoma
    Yi-Jun Kim, Jin Ho Kim
    Scientific Reports.2020;[Epub]     CrossRef
  • Identification of differentially expressed circular RNAs in human nasopharyngeal carcinoma
    Hanwei Wu, Yuchen Liu, Hongfang Duan, Xiaoqin Fan, Yujie Wang, Jian Song, Jinghong Han, Ming Yang, Lu Lu, Guohui Nie
    Cancer Biomarkers.2020; 29(4): 483.     CrossRef
  • PP‐22 promotes autophagy and apoptosis in the nasopharyngeal carcinoma cell line CNE‐2 by inducing endoplasmic reticulum stress, downregulating STAT3 signaling, and modulating the MAPK pathway
    Gui‐Xiang Tan, Xin‐Ning Wang, Yun‐Yun Tang, Wan‐Jing Cen, Zhen‐Hua Li, Guo‐Cai Wang, Jian‐Wei Jiang, Xi‐Cheng Wang
    Journal of Cellular Physiology.2019; 234(3): 2618.     CrossRef
  • microRNA-342-3p targets FOXQ1 to suppress the aggressive phenotype of nasopharyngeal carcinoma cells
    Zheqing Cui, Yulin Zhao
    BMC Cancer.2019;[Epub]     CrossRef
  • Changing odds of survival over time among patients undergoing surgical resection of extremity soft tissue sarcoma
    Yongsung Kim, Han‐Soo Kim, Hwan Seong Cho, Ilkyu Han
    Journal of Surgical Oncology.2019; 120(2): 193.     CrossRef
  • Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma
    Elaine Johanna Limkin, Pierre Blanchard
    The British Journal of Radiology.2019;[Epub]     CrossRef
  • Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma
    Wen Wen, Shi-Juan Mai, Huan-Xin Lin, Mei-Yin Zhang, Jia-Ling Huang, Xin Hua, Chao Lin, Zhi-Qing Long, Zi-Jian Lu, Xiao-Qing Sun, Sai-Lan Liu, Qi Yang, Qian Zhu, Hui-Yun Wang, Ling Guo
    Journal of Translational Medicine.2019;[Epub]     CrossRef
  • Utility of Serum EB Virus Zta Antibody in the Diagnostic of Nasopharyngeal Carcinoma: Evidences From 2,126 Cases and 15,644 Controls
    Guangying Zhang, Zhanzhan Li, Qin Zhou
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Impact of age on survival of locoregional nasopharyngeal carcinoma: An analysis of the Surveillance, Epidemiology, and End Results program database, 2004‐2013
    S.‐J. Huang, Y.‐Y. Tang, H.‐M. Liu, G.‐X. Tan, X. Wang, H. Zhang, F. Yang, S. Yang
    Clinical Otolaryngology.2018; 43(5): 1209.     CrossRef
  • Conditional survival in patients with gallbladder cancer
    Yi-Jun Kim, Kyubo Kim
    Chinese Journal of Cancer.2017;[Epub]     CrossRef
  • 27,771 View
  • 326 Download
  • 30 Web of Science
  • 28 Crossref
Close layer
The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients
Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Ming-Yuan Chen, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Jing Tan, Shuai Chen, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma, Hai-Qiang Mai
Cancer Res Treat. 2018;50(1):19-29.   Published online April 5, 2017
DOI: https://doi.org/10.4143/crt.2016.595
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study was conducted to evaluate the prognostic value of treatment-related lymphopenia in patients with nasopharyngeal carcinoma (NPC).
Materials and Methods
A total of 413 consecutive stage II-IVb NPC patients treated with concurrent chemoradiotherapy (CCRT) were enrolled. The overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) were calculated with the Kaplan-Meier method, and differences were compared using the log-rank test.
Results
A minimum (mini)–absolute lymphocyte counts (ALC) of < 390 cells/μL or ALC after 3 months of CCRT (post3m-ALC) < 705 cells/μL was significantly associated with worse outcome than mini-ALC ≥ 390 cells/μL (OS, p=0.002; PFS, p=0.005; DMFS, p=0.004) or post3m-ALC ≥ 705 cells/μL (OS, p < 0.001; PFS, p < 0.001; DMFS, p=0.001). Patients with lymphopenia (mini-ALC < 390 cells/μL and post3m-ALC < 705 cells/μL) had a worse prognosis than those without lymphopenia (mini-ALC ≥ 390 cells/μL and post3m-ALC ≥ 705 cells/μL) (OS, p < 0.001; PFS, p < 0.001; DMFS, p < 0.001). Multivariate analysis revealed that post3m-ALC was an independent prognostic factor for OS (hazard ratio [HR], 1.76; 95% confidence interval [CI], 1.12 to 2.78; p=0.015), PFS (HR, 1.86; 95% CI, 1.23 to 2.82; p=0.003), and DMFS (HR, 1.87; 95% CI, 1.13 to 3.08; p=0.014). Multivariate analysis also revealed that patients with lymphopenia had a high risk of death (HR, 3.79; 95% CI, 1.75 to 8.19; p=0.001), disease progression (HR, 2.93; 95% CI, 1.59 to 5.41; p=0.001), and distant metastasis (HR, 3.89; 95% CI, 1.67 to 9.10; p=0.002). Multivariate analysis performed with time dependent Cox regression demonstrated ALC was an independent prognostic factor for OS (HR, 0.995; 95% CI, 0.991 to 0.999; p=0.025) and PFS (HR, 0.993; 95% CI, 0.988 to 0.998; p=0.006).
Conclusion
Treatment-related lymphopenia was a poor prognostic factor in NPC patients.

Citations

Citations to this article as recorded by  
  • [18F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinoma
    Li-Ting Liu, Zhen-Chong Yang, Jia-Rui He, Hao-Xiang Long, Ying-Ying Hu, Jia-Yi Shen, Mei-Juan Luo, Yu-Chen Li, Xu Zhang, Su-Chen Li, Zi-Jian Lu, Bei-Bei Xiao, Jin-Hao Yang, Xiao-Fei Lv, Yu-Jing Liang, Shan-Shan Guo, Sai-Lan Liu, Xue-Song Sun, Xiao-Yun Li,
    European Journal of Nuclear Medicine and Molecular Imaging.2026; 53(3): 1498.     CrossRef
  • Radiation-induced lymphopenia: A data compilation to unveil relevant factors and mitigation strategies
    Vladislav Sandul, Sarah Salih Al-Hamami, Jiří Kubeš, Marco Durante, Thomas Friedrich
    Clinical and Translational Radiation Oncology.2026; 56: 101071.     CrossRef
  • Deep learning-based prediction of dynamic blood dose estimates for head-and-neck cancer
    Hoyeon Lee, Sebastian Tattenberg
    Physics in Medicine & Biology.2026; 71(1): 015024.     CrossRef
  • Severe radiation-induced lymphopenia and its impact on overall survival in solid tumors: A scoping review of systematic reviews
    Shen Zhang, Sheen Dube, Saranya Kakumanu, Vibhay Pareek
    Journal of Cancer Research and Therapeutics.2026; 22(1): 3.     CrossRef
  • The Prognostic Value of EDRIC and Its Association With Radiation‐Induced Lymphopenia in Patients With Esophageal Cancer Undergoing Radical Radiotherapy: A Single‐Center Chinese Study
    Yue Ke, Chen Yang, Yu‐Xing Li, Xiao‐Xiao Liu, Xiao Liu, Jia‐Min Gao, Hong‐Bing Ma
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Impact of circulating lymphocyte kinetics following radiotherapy on patient survival: A model-based meta-analysis
    Thao-Nguyen Pham, Julie Coupey, Juliette Thariat, Samuel Valable
    Computers in Biology and Medicine.2025; 186: 109702.     CrossRef
  • Relationship Between Elective Neck Irradiation and Severe Lymphopenia in Patients Treated With Head and Neck Chemoradiotherapy
    T.A. Mickel, D.H. Moon, V. Avkshtol, N.-L. Pham, J.L. Shah, R.S. Hughes, B.D. Sumer, D.J. Sher
    Clinical Oncology.2025; 44: 103873.     CrossRef
  • Effects of radiotherapy on lymphocytes in patients with middle and lower esophageal cancer and its relationship with prognosis
    Shu-Guang Li, Yang Liu, Xue-Yuan Zhang, You-Mei Li, Wen-Bin Shen, Shu-Chai Zhu
    World Journal of Gastrointestinal Oncology.2025;[Epub]     CrossRef
  • Tumor Site–Specific Radiation-Induced Lymphocyte Depletion Models After Fractionated Radiotherapy: Considerations of Model Structure From an Aggregate Data Meta-Analysis
    Thao-Nguyen Pham, Julie Coupey, Samuel Valable, Juliette Thariat
    JCO Clinical Cancer Informatics.2025;[Epub]     CrossRef
  • Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma
    Jianyun Jiang, Ruiping Zhai, Fangfang Kong, Chengrun Du, Hongmei Ying
    European Archives of Oto-Rhino-Laryngology.2024; 281(1): 181.     CrossRef
  • Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study
    Wei-Wei Zhang, Jia-Yi Lin, Gao-Yuan Wang, Cheng-Long Huang, Ling-Long Tang, Yan-Ping Mao, Guan-Qun Zhou, Li-Zhi Liu, Li Tian, Ji-Bin Li, Jun Ma, Rui Guo
    Radiotherapy and Oncology.2024; 194: 110189.     CrossRef
  • Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial
    Cheng-Long Huang, Ning Zhang, Wei Jiang, Fang-Yun Xie, Xiao-Qing Pei, Shao Hui Huang, Xue-Yan Wang, Yan-Ping Mao, Kun-Peng Li, Qing Liu, Ji-Bin Li, Shao-Qiang Liang, Guan-Jie Qin, Wei-Han Hu, Guan-Qun Zhou, Jun Ma, Ying Sun, Lei Chen, Ling-Long Tang
    Journal of Clinical Oncology.2024; 42(17): 2021.     CrossRef
  • Immunological effects of radiopharmaceutical therapy
    Amanda G. Shea, Malick Bio Idrissou, Ana Isabel Torres, Tessa Chen, Reiner Hernandez, Zachary S. Morris, Quaovi H. Sodji
    Frontiers in Nuclear Medicine.2024;[Epub]     CrossRef
  • Current Status and Future Directions of Proton Therapy for Head and Neck Carcinoma
    Sara Lillo, Alfredo Mirandola, Alessandro Vai, Anna Maria Camarda, Sara Ronchi, Maria Bonora, Rossana Ingargiola, Barbara Vischioni, Ester Orlandi
    Cancers.2024; 16(11): 2085.     CrossRef
  • Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis
    Ke-gui Weng, Hai-ke Lei, De-Song Shen, Ying Wang, Xiao-Dong Zhu
    Cancer Management and Research.2024; Volume 16: 603.     CrossRef
  • A prognostic nomogram for patients with III–IV nasopharyngeal carcinoma based on dynamic changes in the inflammatory and nutrition index
    Guangyi Cheng, Shiwang Yuan, Jiang Wang, Sijia Deng, Yang Wu, Yuyan Wang, Yu Shen, Liantao Li
    Clinical and Translational Oncology.2024; 27(6): 2638.     CrossRef
  • Impact of Radiation Dose to Circulating Immune Cells on Tumor Control and Survival in Esophageal Cancer
    Shang Cai, Yawen Fan, Qi Guo, Yanze Sun, Peifeng Zhao, Ye Tian, Qiuhong Fan
    Cancer Biotherapy and Radiopharmaceuticals.2023; 38(6): 380.     CrossRef
  • Meta-analysis and Critical Review: Association Between Radio-induced Lymphopenia and Overall Survival in Solid Cancers
    Yasmine El Houat, Christophe Massard, Veronique Quillien, Renaud de Crevoisier, Joël Castelli
    Advances in Radiation Oncology.2023; 8(2): 101038.     CrossRef
  • The prognostic predictive value of systemic immune index and systemic inflammatory response index in nasopharyngeal carcinoma: A systematic review and meta-analysis
    Li Wang, Xianfei Qin, Yu Zhang, Shouyu Xue, Xicheng Song
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Prognostic Significance of the Post-Treatment Neutrophil-to-Lymphocyte Ratio in Pharyngeal Cancers Treated with Concurrent Chemoradiotherapy
    Ji Min Yun, Man Ki Chung, Chung Hwan Baek, Young Ik Son, Myung Ju Ahn, Dongryul Oh, Ki Won Kim, Yoon Kyoung So
    Cancers.2023; 15(4): 1248.     CrossRef
  • Analysis of risk characteristics for metachronous metastasis in different period of nasopharyngeal carcinoma
    Zhaodong Fei, Huiling Hong, Ting Xu, Yiying Xu, Jiawei Chen, Xiufang Qiu, Jianming Ding, Ye Feng, Chaoxiong Huang, Li Li, Mengying Li, Chuanben Chen
    BMC Cancer.2023;[Epub]     CrossRef
  • Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma
    Jianjian Qiu, Hancui Lin, Dongmei Ke, Yilin Yu, Jiaying Xu, Hejin Qiu, Qunhao Zheng, Hui Li, Hongying Zheng, Lingyun Liu, Zhiping Wang, Qiwei Yao, Jiancheng Li
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Prognostic value of absolute lymphocyte count in oral cavity squamous cell carcinoma
    Rema Shah, Christina Liu, Hemali P. Shah, Benjamin L. Judson
    Laryngoscope Investigative Otolaryngology.2023; 8(4): 870.     CrossRef
  • Dosimetric Effect of Thymus and Thoracic Duct on Radiation-Induced Lymphopenia in Patients With Primary Lung Cancer Who Received Thoracic Radiation
    Jinliang Zhang, Li Yang, Hui Li, Jeff W. Chan, Eric K.W. Lee, Min Liu, Lingyu Ma, Qin Liu, Jian-Yue Jin, Pingfu Fu, Zhiyuan Xu, Feng-Ming (Spring) Kong
    Advances in Radiation Oncology.2023; 8(6): 101260.     CrossRef
  • Lymphopénie radio-induite : les lymphocytes comme nouvel organe à risque
    P.A. Laurent, É. Deutsch
    Cancer/Radiothérapie.2023; 27(6-7): 511.     CrossRef
  • Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape
    Yuanyuan Ma, Chang Guo, Xijun Wang, Xundong Wei, Jie Ma
    Journal of Experimental & Clinical Cancer Research.2023;[Epub]     CrossRef
  • CT-based dosiomics and radiomics model predicts radiation-induced lymphopenia in nasopharyngeal carcinoma patients
    Qingfang Huang, Chao Yang, Jinmeng Pang, Biao Zeng, Pei Yang, Rongrong Zhou, Haijun Wu, Liangfang Shen, Rong Zhang, Fan Lou, Yi Jin, Albert Abdilim, Hekun Jin, Zijian Zhang, Xiaoxue Xie
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Developing the POTOMAC Model: A Novel Prediction Model to Study the Impact of Lymphopenia Kinetics on Survival Outcomes in Head and Neck Cancer Via an Ensemble Tree-Based Machine Learning Approach
    Carmen Kut, Doug Midthune, Emerson Lee, Peyton Fair, Tia Cheunkarndee, Todd McNutt, Theodore DeWeese, Carole Fakhry, Victor Kipnis, Harry Quon
    JCO Clinical Cancer Informatics.2023;[Epub]     CrossRef
  • Preoperative prognostic nutritional index predicts prognosis of patients with oral cavity cancer
    Ku‐Hao Fang, Sheng‐Wei Chang, Yi‐Chan Lee, Ethan I. Huang, Chia‐Hsuan Lai, Geng‐He Chang, Ming‐Shao Tsai, Cheng‐Ming Hsu, Yao‐Te Tsai
    Oral Diseases.2022; 28(7): 1816.     CrossRef
  • A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma
    Yajing Zhang, Yujie Zhu, Jiaqi Wang, Yi Xu, Zekun Wang, Yang Liu, Xuebing Di, Lin Feng, Ye Zhang
    Cancer Immunology, Immunotherapy.2022; 71(3): 675.     CrossRef
  • Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein‐Barr virus DNA
    Li‐Ting Liu, Yu‐Jing Liang, Shan‐Shan Guo, Yao Xie, Guo‐Dong Jia, Dong‐Xiang Wen, Lin‐Quan Tang, Qiu‐Yan Chen, Hai‐Qiang Mai
    Head & Neck.2022; 44(1): 34.     CrossRef
  • Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis
    Chengrun Du, Mengshan Ni, Jianyun Jiang, Fangfang Kong, Ruiping Zhai, Yingchen Lv, Chaosu Hu, Hongmei Ying
    European Archives of Oto-Rhino-Laryngology.2022; 279(8): 3947.     CrossRef
  • The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis
    Dongjun Dai, Qiaoying Tian, Yongjie Shui, Jinfan Li, Qichun Wei
    Radiotherapy and Oncology.2022; 168: 28.     CrossRef
  • Systematic construction and external validation of an immune‐related prognostic model for nasopharyngeal carcinoma
    Weiqun Lin, Di Cao, Annan Dong, Shaobo Liang, Yongyi Zhao, Cuibing Liu, Yinghua Yan, Xiaoliu Luo, Lizhi Liu, Xinchen Zeng, Qiaowen Ou
    Head & Neck.2022; 44(5): 1086.     CrossRef
  • Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer
    Fang Chen, Jian-Yue Jin, Timothy S.K. Hui, Haiman Jing, Hong Zhang, Yaqing Nong, Ying Han, Weili Wang, Lingyu Ma, Fan Yi, Qingqing Chen, Yongsheng Zhang, Pingfu Fu, Li Yang, Zhiyuan Xu, Feng-Ming Spring Kong
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • RuleFit-Based Nomogram Using Inflammatory Indicators for Predicting Survival in Nasopharyngeal Carcinoma, a Bi-Center Study
    Chao Luo, Shuqi Li, Qin Zhao, Qiaowen Ou, Wenjie Huang, Guangying Ruan, Shaobo Liang, Lizhi Liu, Yu Zhang, Haojiang Li
    Journal of Inflammation Research.2022; Volume 15: 4803.     CrossRef
  • Head and neck cancers volume reduction: should we reduce our prophylactic node radiation to spare the antitumor immune response?
    Y. El Houat, L. Bouvier, M. Baty, X. Palard-Novello, Y. Pointreau, R. de Crevoisier, J. Castelli
    Cancer/Radiothérapie.2022; 26(6-7): 916.     CrossRef
  • Establishment of a prognostic nomogram for patients with locoregionally advanced nasopharyngeal carcinoma incorporating clinical characteristics and dynamic changes in hematological and inflammatory markers
    Qin Liu, Lingyu Ma, Huangrong Ma, Li Yang, Zhiyuan Xu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers
    Ava Saidian, Isabella Dolendo, Andrew Sharabi, Tyler F. Stewart, Brent Rose, Rana R. McKay, Aditya Bagrodia, Amirali Salmasi
    Cancers.2022; 15(1): 127.     CrossRef
  • Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients
    FangJie Liu, YingJia Wu, JianHui Shao, Bo Qiu, SuPing Guo, QiaoTing Luo, JinYu Guo, DaQuan Wang, Chu Chu, Rui Zhou, NaiBin Chen, XinLei Ai, Hui Liu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response
    Mame Daro-Faye, Wassim Kassouf, Luis Souhami, Gautier Marcq, Fabio Cury, Tamim Niazi, Paul Sargos
    World Journal of Urology.2021; 39(5): 1331.     CrossRef
  • Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes
    Hui Xu, Maosheng Lin, Yingying Hu, Li Zhang, Qiaoqiao Li, Jinhan Zhu, Shi Wang, Mian Xi
    The Oncologist.2021; 26(3): e425.     CrossRef
  • Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy
    Michael I. Koukourakis, Alexandra Giatromanolaki
    Critical Reviews in Oncology/Hematology.2021; 159: 103226.     CrossRef
  • Hematological toxicity in patients with solid malignant tumors treated with radiation – Temporal analysis, dose response and impact on survival
    Cynthia Terrones-Campos, Bruno Ledergerber, Ivan Richter Vogelius, Marie Helleberg, Lena Specht, Jens Lundgren
    Radiotherapy and Oncology.2021; 158: 175.     CrossRef
  • Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study
    Wang Jing, Yufei Liu, Hui Zhu, James Welsh, Saumil Gandhi, Melenda Jeter, Quynh Nguyen, Aileen B. Chen, Michael O'Reilly, Zhongxing Liao, Joe Y. Chang, Percy Lee, Steven H. Lin
    Clinical and Translational Radiation Oncology.2021; 28: 54.     CrossRef
  • Prognostic value of neutrophils for patients with nasopharyngeal carcinoma
    Lisha Chen, Mengying Li, Ting Xu, Xiufang Qiu, Chuanben Chen
    Laryngoscope Investigative Otolaryngology.2021; 6(2): 219.     CrossRef
  • The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis
    Pim J.J. Damen, Tiuri E. Kroese, Richard van Hillegersberg, Ewoud Schuit, Max Peters, Joost J.C. Verhoeff, Steven H. Lin, Peter S.N. van Rossum
    International Journal of Radiation Oncology*Biology*Physics.2021; 111(4): 936.     CrossRef
  • Prognostic Significance of Circulating Lymphocyte Subsets Before Treatment in Patients with Nasopharyngeal Carcinoma
    De-Song Shen, Chang Yan, Yu Liang, Kai-Hua Chen, Xiao-Dong Zhu
    Cancer Management and Research.2021; Volume 13: 8109.     CrossRef
  • Proton therapy for locally advanced non-small cell lung cancer
    Olsi Gjyshi, Zhongxing Liao
    The British Journal of Radiology.2020;[Epub]     CrossRef
  • Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis
    Jiawen Zhao, Weijia Huang, Yongxian Wu, Yihuan Luo, Bo Wu, Jiwen Cheng, Junqiang Chen, Deyun Liu, Chengyang Li
    Cancer Cell International.2020;[Epub]     CrossRef
  • Prognosis and Risk Factors of Radiation-Induced Lymphopenia in Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy
    Qianqian Zhao, Tingting Li, Gang Chen, Zhaochong Zeng, Jian He
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram
    Peter S.N. van Rossum, Wei Deng, David M. Routman, Amy Y. Liu, Cai Xu, Yutaka Shiraishi, Max Peters, Kenneth W. Merrell, Christopher L. Hallemeier, Radhe Mohan, Steven H. Lin
    Practical Radiation Oncology.2020; 10(1): e16.     CrossRef
  • Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count
    Xiaoxue Xie, Shenglan Gong, Hekun Jin, Pei Yang, Ting Xu, Yilong Cai, Chengxian Guo, Rong Zhang, Fan Lou, Wenjuan Yang, Hui Wang
    Radiation Oncology.2020;[Epub]     CrossRef
  • Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer
    Yasunori Yoshino, Ayumi Taguchi, Maki Takao, Tomoko Kashiyama, Akiko Furusawa, Masaya Uno, Satoshi Okada, Nao Kino, Toshiharu Yasugi
    International Journal of Clinical Oncology.2019; 24(4): 428.     CrossRef
  • Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer
    Michael D. Schad, Sunil W. Dutta, Donald M. Muller, Krishni Wijesooriya, Timothy N. Showalter
    Advances in Radiation Oncology.2019; 4(2): 323.     CrossRef
  • Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era
    Hwa Kyung Byun, Nalee Kim, Hong In Yoon, Seok-Gu Kang, Se Hoon Kim, Jaeho Cho, Jong Geol Baek, Jong Hee Chang, Chang-Ok Suh
    Radiation Oncology.2019;[Epub]     CrossRef
  • Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma
    Hwa Kyung Byun, Nalee Kim, Sangjoon Park, Jinsil Seong
    Strahlentherapie und Onkologie.2019; 195(11): 1007.     CrossRef
  • Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy
    Qiaoqiao Li, Sha Zhou, Shiliang Liu, Songran Liu, Hong Yang, Lei Zhao, Mengzhong Liu, Yonghong Hu, Mian Xi
    Annals of Surgical Oncology.2019; 26(9): 2882.     CrossRef
  • Assessing the interactions between radiotherapy and antitumour immunity
    Clemens Grassberger, Susannah G. Ellsworth, Moses Q. Wilks, Florence K. Keane, Jay S. Loeffler
    Nature Reviews Clinical Oncology.2019; 16(12): 729.     CrossRef
  • Overview of Hematopoietic Stem Cells in Systemic Cancer Treatment, Aging, Pregnancy, and Radiation Hormesis
    Aleksei N. Shoutko
    Advances in Molecular Imaging.2019; 09(02): 19.     CrossRef
  • Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma
    Sangjoon Park, Hwa Kyung Byun, Jinsil Seong
    Liver Cancer.2019; 8(6): 468.     CrossRef
  • Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
    Cheng Xu, Shi-Ping Yang, Yuan Zhang, Ling-Long Tang, Guan-Qun Zhou, Xu Liu, Yan-Ping Mao, Rui Guo, Wen-Fei Li, Lei Chen, Ai-Hua Lin, Ying Sun, Jun Ma
    Cancer Research and Treatment.2018; 50(3): 777.     CrossRef
  • Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors
    Susannah G. Ellsworth
    Advances in Radiation Oncology.2018; 3(4): 512.     CrossRef
  • Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
    Anne Rodallec, Guillaume Sicard, Raphaelle Fanciullino, Sébastien Benzekry, Bruno Lacarelle, Gerard Milano, Joseph Ciccolini
    Expert Opinion on Drug Metabolism & Toxicology.2018; : 1.     CrossRef
  • 15,935 View
  • 377 Download
  • 69 Web of Science
  • 64 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
Subscribe to the CRT Newsletter
Stay up to date with the latest advances in oncology.
Receive new issue alerts, featured articles,
and important announcements
from Cancer Research and Treatment.
TOP